<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6016963</article-id><article-id pub-id-type="doi">10.3390/molecules23020395</article-id><article-id pub-id-type="publisher-id">molecules-23-00395</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9481-8281</contrib-id><name><surname>Hendriks</surname><given-names>Wiljan</given-names></name><xref ref-type="aff" rid="af1-molecules-23-00395">1</xref><xref rid="c1-molecules-23-00395" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Bourgonje</surname><given-names>Annika</given-names></name><xref ref-type="aff" rid="af1-molecules-23-00395">1</xref></contrib><contrib contrib-type="author"><name><surname>Leenders</surname><given-names>William</given-names></name><xref ref-type="aff" rid="af2-molecules-23-00395">2</xref></contrib><contrib contrib-type="author"><name><surname>Pulido</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="af3-molecules-23-00395">3</xref><xref ref-type="aff" rid="af4-molecules-23-00395">4</xref></contrib></contrib-group><aff id="af1-molecules-23-00395"><label>1</label>Department of Cell Biology, Radboud University Medical Center, Geert Grooteplein 26, 6525 GA Nijmegen, The Netherlands; <email>annika.bourgonje@radboudumc.nl</email></aff><aff id="af2-molecules-23-00395"><label>2</label>Department of Biochemistry, Radboud University Medical Center, Geert Grooteplein 26, 6525 GA Nijmegen, The Netherlands; <email>william.leenders@radboudumc.nl</email></aff><aff id="af3-molecules-23-00395"><label>3</label>Biomarkers in Cancer Unit, Biocruces Health Research Institute, 48903 Barakaldo, Spain</aff><aff id="af4-molecules-23-00395"><label>4</label>IKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Spain; <email>rpulidomurillo@gmail.com</email></aff><author-notes><corresp id="c1-molecules-23-00395"><label>*</label>Correspondence: <email>wiljanjaj.hendriks@radboudumc.nl</email>; Tel.: +31-24-361-4329</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2018</year></pub-date><volume>23</volume><issue>2</issue><elocation-id>395</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>09</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#169; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Proper control of the phosphotyrosine content in signal transduction proteins is essential for normal cell behavior and is lost in many pathologies. Attempts to normalize aberrant tyrosine phosphorylation levels in disease states currently involve either the application of small compounds that inhibit tyrosine kinases (TKs) or the addition of growth factors or their mimetics to boost receptor-type TK activity. Therapies that target the TK enzymatic counterparts, the multi-enzyme family of protein tyrosine phosphatases (PTPs), are still lacking despite their undisputed involvement in human diseases. Efforts to pharmacologically modulate PTP activity have been frustrated by the conserved structure of the PTP catalytic core, providing a daunting problem with respect to target specificity. Over the years, however, many different protein interaction-based regulatory mechanisms that control PTP activity have been uncovered, providing alternative possibilities to control PTPs individually. Here, we review these regulatory principles, discuss existing biologics and proteinaceous compounds that affect PTP activity, and mention future opportunities to drug PTPs via these regulatory concepts.</p></abstract><kwd-group><kwd>biologics</kwd><kwd>PDZ domain</kwd><kwd>protein inhibitors</kwd><kwd>protein tyrosine kinases</kwd><kwd>protein&#8211;protein interaction</kwd><kwd>regulation of activity</kwd><kwd>signal transduction</kwd></kwd-group></article-meta></front><body><sec id="sec1-molecules-23-00395"><title>1. Introduction</title><p>Cells integrate internal and external signals into appropriate adaptive responses. This signal processing should be timely and efficient, both from an economic and logistic point of view. Cells cannot rely on time-consuming de novo synthesis of RNA and protein components when fast responses are needed. Rather, they make use of a plethora of&#8212;often reversible&#8212;ways to modify biomolecules. One of the most abundant and best studied posttranslational protein modifications in signal transduction is reversible phosphorylation of serine, threonine and tyrosine residues. Protein phosphorylation is key in virtually all cellular processes [<xref rid="B1-molecules-23-00395" ref-type="bibr">1</xref>], and especially phosphotyrosine-dependent events are associated with signaling networks that drive proliferation and differentiation of cells in multi-cellular organisms. Therefore, a considerable part of the hereditary and acquired diseases in humans are caused by defects in phosphotyrosine signaling relays [<xref rid="B2-molecules-23-00395" ref-type="bibr">2</xref>,<xref rid="B3-molecules-23-00395" ref-type="bibr">3</xref>]. </p><p>The specific phosphorylation status of proteins within cells is tightly controlled by opposing kinase and phosphatase activities. Protein tyrosine kinases (TKs) add phosphate groups to selected tyrosine residues on proteins. Vice versa, members of the highly conserved protein tyrosine phosphatase (PTP) family dephosphorylate these phosphotyrosine sites. One should not conclude, however, that PTPs merely oppose TK functions; multiple examples exist that demonstrate that TKs and PTPs may also act in concert. Most phosphorylation events do not just target a single signaling pathway in the cell but have modulating effects that spread across multiple interconnected networks, thereby changing signaling specificity and outcome. Generally speaking, kinases are thought to control the amplitude of a certain signaling response and phosphatases are rather determining the response rate and duration [<xref rid="B4-molecules-23-00395" ref-type="bibr">4</xref>,<xref rid="B5-molecules-23-00395" ref-type="bibr">5</xref>]. </p><p>PTPs are evolutionary well preserved proteins that share a conserved region in their catalytic site (CX<sub>5</sub>R) containing an essential cysteine residue, which is responsible for removing the phosphate group from phosphorylated tyrosine residues. PTPs can be classified into several classes. Class I PTPs represent the largest group in which a distinction can be made between cytosolic non-receptor PTPs, transmembrane receptor PTPs (RPTPs) and dual-specificity PTPs (DUSPs). The dual-specificity subgroup can be further subdivided into MAPK phosphatases (MKPs), PTEN-related phosphatases (PTENs), phosphatases of regenerating liver (PRLs), myotubularin-related phosphatases (MTMRs) and atypical PTPs. The remaining cysteine-based classes are much smaller and consist of low-molecular weight (lmw) PTP (class II) and cell division cycle (cdc25) (class III). There is molecular evolutionary and enzymatic evidence to also include the haloacid dehalogenase (HAD), phosphoglycerate mutase (PGM) and acid phosphatase (ACP) families as PTPs. Instead of cysteine, these enzymes exploit aspartate (HAD) or histidine (PGM and ACP) in their PTP active site. In total, this brings the human PTP superfamily to the level of 125 protein-encoding genes [<xref rid="B6-molecules-23-00395" ref-type="bibr">6</xref>] (<xref ref-type="fig" rid="molecules-23-00395-f001">Figure 1</xref>).</p><p>When analyzing the gene build-up within the PTP superfamily, it becomes apparent that nature invented these enzyme machines several times independently, but in all cases ended up with a so-called P-loop that harnesses the active site residue and a general acid/base-containing WPD loop involved in substrate binding. The evolutionary history of involved genes thus represents an impressive example of convergent evolution [<xref rid="B7-molecules-23-00395" ref-type="bibr">7</xref>,<xref rid="B8-molecules-23-00395" ref-type="bibr">8</xref>]. The PTP active site is formed by a 0.5&#8211;1.0 nm deep cleft that is optimized to accommodate the substrate&#8217;s phospho-residue and to facilitate its dephosphorylation. The latter occurs via a two-step reaction that involves: (i) the formation of a covalent phosphoryl enzyme intermediate; and (ii) the subsequent water-mediated hydrolysis to release the phosphate ion from the enzyme. This very conserved efficient overall catalytic mechanism has rendered the design of specific catalytic inhibitors for individual family members to be very difficult [<xref rid="B9-molecules-23-00395" ref-type="bibr">9</xref>,<xref rid="B10-molecules-23-00395" ref-type="bibr">10</xref>]. Not surprisingly, the protein phosphatases family was not represented in Hopkins and Groom&#8217;s overview of the druggable genome [<xref rid="B11-molecules-23-00395" ref-type="bibr">11</xref>] but recent developments challenge their stigma of being undruggable [<xref rid="B12-molecules-23-00395" ref-type="bibr">12</xref>]. Other contributions in this Special Issue highlight steps and breakthroughs in the research towards small-molecule inhibitors for PTPs. Here we will concentrate on the development of protein-based drugs that modulate PTP activity by interfering with protein&#8211;protein interactions (PPIs). Before doing so we will first briefly introduce the PPI-based regulatory principles that steer PTP action. </p></sec><sec id="sec2-molecules-23-00395"><title>2. Inhibiting and Augmenting PTP Activities</title><p>Two discoveries launched major pharmaceutical attempts to search for PTP inhibitors: the finding that PTP1B knockout mice are insulin hypersensitive and lost the ability to become obese [<xref rid="B13-molecules-23-00395" ref-type="bibr">13</xref>,<xref rid="B14-molecules-23-00395" ref-type="bibr">14</xref>] and the notion that <italic>SHP2</italic> classified as an oncogene [<xref rid="B15-molecules-23-00395" ref-type="bibr">15</xref>]. Envisaged small-molecule inhibitors were meant to block enzyme activity in order to treat type 2 diabetes and obesity or cancer. As mentioned, the conserved structure of the PTP domain poses a considerable problem regarding drug specificity. To circumvent this hurdle, antisense oligonucleotide treatment to reduce protein&#8212;and thus activity&#8212;levels have been explored in mice for PTP1B [<xref rid="B16-molecules-23-00395" ref-type="bibr">16</xref>] and lmwPTP [<xref rid="B17-molecules-23-00395" ref-type="bibr">17</xref>]. The difficulty of in vivo delivery of antisense oligonucleotides, however, has led to continuing efforts to generate small-compound inhibitors, and clinical trials with drugs that display sufficient specificity towards VEPTP [<xref rid="B12-molecules-23-00395" ref-type="bibr">12</xref>], PTP1B and SHP2 [<xref rid="B18-molecules-23-00395" ref-type="bibr">18</xref>] are now underway. </p><p>There are multiple PTPs for which the signaling role rather fits the tyrosine kinase opposing, tumor suppressive description. Therapeutic intervention then requires the development of drugs that boost the activity of specific PTPs. Replenishment of PTP activity is also needed following their transient oxidation and inactivation resulting from the local peak in intracellular H<sub>2</sub>O<sub>2</sub> production that parallels physiological phosphotyrosine-based signal transduction [<xref rid="B19-molecules-23-00395" ref-type="bibr">19</xref>]. This redox sensitivity of PTP enzymes is attributable to the build-up of the active site, in which the essential cysteine residue experiences a slightly acidic environment and is predominantly in the thiolate form. This serves well as a nucleophile in the two-step dephosphorylation reaction mechanism that characterizes PTPs but it also causes oxidation vulnerability. Many PTPs appear constitutively active when studied in isolation but evidence is accumulating that they are often regulated by intra- and intermolecular interactions. Increased knowledge of such regulatory mechanisms will ultimately allow the development of therapeutics, be it small-molecule or biomolecule-derived compounds, that enable the fine-tuning of specific PTP activities at will. Some PTPs demonstrate impressive protein&#8211;protein anchoring and scaffolding potential and therefore PTP activity may extend beyond enzymatic handling of phosphotyrosine-containing proteins. An example is provided by the &#8220;moonlighting&#8221; activities of the well-known tumor suppressor protein phosphatase and tensin homolog (PTEN) that include protein phosphatase as well as lipid phosphatase activity, and, in addition, non-catalytic nuclear roles in supporting chromosomal stability and maintenance of genome integrity [<xref rid="B20-molecules-23-00395" ref-type="bibr">20</xref>,<xref rid="B21-molecules-23-00395" ref-type="bibr">21</xref>]. While reviewing the protein interaction-based PTP regulatory mechanisms (see also <xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>), we will therefore mention those that impact on enzyme activity and the ones that impinge on the protein&#8211;protein interactive capacities.</p><sec id="sec2dot1-molecules-23-00395"><title>2.1. Intra-Molecular (Allosteric) Regulation of PTP Activity</title><p>The proto-oncogene <italic>PTPN11</italic> encodes SHP2, a ubiquitously expressed cytosolic PTP that has its enzymatic phosphotyrosine phosphatase domain N-terminally preceded by two SH2 domains. SHP2 is in an inactive state when its N-terminal SH2 domain folds onto the PTP domain, thereby blocking the PTP active site and preventing substrate binding (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>E). Following growth factor receptor activation specific phosphotyrosine motifs in the receptor TKs and in their substrates, including docking adapter proteins, will lure the SHP2 N-terminal SH2 domain away from the PTP domain, unleashing the domain&#8217;s activity [<xref rid="B22-molecules-23-00395" ref-type="bibr">22</xref>]. <italic>PTPN11</italic> mutations are found in patients with Noonan Syndrome (NS), Leopard Syndrome (LS), juvenile myelomonocytic leukemia (JMML), acute myelogenous leukemia (AML) and various solid tumors [<xref rid="B2-molecules-23-00395" ref-type="bibr">2</xref>]. At the protein level, these mutations disrupt the allosteric interaction and cause SHP2 to be constitutively active [<xref rid="B23-molecules-23-00395" ref-type="bibr">23</xref>]. Thus, inhibiting SHP2 activity is a promising strategy to treat various cancers. Apart from drugs directly aiming at the active site, indeed small-molecule SHP2 inhibitors that in fact &#8220;glue&#8221; the enzyme in its inactive conformation have been developed [<xref rid="B24-molecules-23-00395" ref-type="bibr">24</xref>,<xref rid="B25-molecules-23-00395" ref-type="bibr">25</xref>,<xref rid="B26-molecules-23-00395" ref-type="bibr">26</xref>]. </p><p>A special group of dual specificity phosphatases (DUSPs) act as mitogen-activated protein kinase phosphatases (MKPs) [<xref rid="B27-molecules-23-00395" ref-type="bibr">27</xref>], and for some of the members, such as MKP-3 (encoded by the <italic>DUSP6</italic> gene), firm proof of a substrate-induced allosteric regulatory mechanism has been provided [<xref rid="B28-molecules-23-00395" ref-type="bibr">28</xref>,<xref rid="B29-molecules-23-00395" ref-type="bibr">29</xref>,<xref rid="B30-molecules-23-00395" ref-type="bibr">30</xref>]. MKPs all have a C-terminal PTP domain, an N-terminus that dictates subcellular localization and in between there is a kinase interaction motif (KIM) that determines MAPK recognition (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>F). MKP3 has a relatively high substrate specificity; it dephosphorylates the activation loop phosphothreonine and phosphotyrosine residues in ERK1/2 [<xref rid="B31-molecules-23-00395" ref-type="bibr">31</xref>]. MKP3 displays low basal enzymatic activity but KIM-mediated binding to its substrate induces a repositioning of key active-site residues that likely facilitate WPD loop closure, boosting its activity and explaining its substrate specificity [<xref rid="B28-molecules-23-00395" ref-type="bibr">28</xref>,<xref rid="B29-molecules-23-00395" ref-type="bibr">29</xref>,<xref rid="B30-molecules-23-00395" ref-type="bibr">30</xref>]. Based on this mechanism, allosteric inhibitors of MKP3 have been developed [<xref rid="B32-molecules-23-00395" ref-type="bibr">32</xref>,<xref rid="B33-molecules-23-00395" ref-type="bibr">33</xref>].</p><p>Most receptor-type PTPs (RPTPs) display tandem phosphatase domains in their intracellular portion; the enzymatic activity is primarily attributable to the membrane proximal domain (D1), while the membrane distal domain (D2) usually is inactive [<xref rid="B34-molecules-23-00395" ref-type="bibr">34</xref>]. It is still a conundrum how the D2 domain contributes to RPTP function. Suggestions converge on regulating D1&#8217;s substrate specificity and/or enzyme activity (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>A). An intriguing example is found in the comparative study on two <italic>Drosophila</italic> RPTPs, DLAR and PTP99A [<xref rid="B35-molecules-23-00395" ref-type="bibr">35</xref>]. Using bacterially produced recombinant RPTP segments in activity and binding assays and subsequent in silico structural studies it was found that the DLAR D2 domain decreased the D1 activity via an inter-domain interaction whereas the PTP99A D2 domain caused an increase in the D1 activity. If and how the linker regions, which connect D1 and D2, are involved in mediating these allosteric effects in DLAR and PTP99A [<xref rid="B36-molecules-23-00395" ref-type="bibr">36</xref>] requires further investigation.</p></sec><sec id="sec2dot2-molecules-23-00395"><title>2.2. Inter-Molecular Regulation of PTP Activity</title><p>Receptor-type TKs become active once ligand binding triggers their dimerization. In contrast, RPTPs present as inactive homodimers [<xref rid="B37-molecules-23-00395" ref-type="bibr">37</xref>,<xref rid="B38-molecules-23-00395" ref-type="bibr">38</xref>] or heterodimers [<xref rid="B39-molecules-23-00395" ref-type="bibr">39</xref>] on the cell surface. It remains to be established whether and how ligand binding is involved (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>B). Structural studies initially suggested that a sequence motif termed &#8220;wedge domain&#8221;, located between the transmembrane region and the D1 domain, is responsible for dimer-induced RPTP inactivation by occluding the catalytic center of D1 in the partner RPTP [<xref rid="B40-molecules-23-00395" ref-type="bibr">40</xref>,<xref rid="B41-molecules-23-00395" ref-type="bibr">41</xref>,<xref rid="B42-molecules-23-00395" ref-type="bibr">42</xref>]. In addition, the activity of RPTPs that do not contain such a wedge domain was found to be reduced upon dimerization (e.g., [<xref rid="B43-molecules-23-00395" ref-type="bibr">43</xref>]). As yet, only a limited number of bona fide RPTP ligands have been identified [<xref rid="B44-molecules-23-00395" ref-type="bibr">44</xref>], and for PTPRZ-B the inhibitory effect of its ligand pleiotrophin on activity has been shown [<xref rid="B45-molecules-23-00395" ref-type="bibr">45</xref>,<xref rid="B46-molecules-23-00395" ref-type="bibr">46</xref>]. In line, dissociation of the dimeric RPTP SAP-1 by a reducing environment results in increased enzymatic activity of SAP-1 monomers [<xref rid="B47-molecules-23-00395" ref-type="bibr">47</xref>].</p><p>Not only transmembrane PTPs form multimers, also some non-receptor type family members present as oligomers. This was first demonstrated for a naturally occurring cytoplasmic variant encoded by the RPTP gene <italic>PTPRE</italic> [<xref rid="B48-molecules-23-00395" ref-type="bibr">48</xref>]. Dimerization tendency of this cyt-PTP epsilon isoform appeared the net result of the impact of its inactive D2 domain, that supported a strong intermolecular interaction inhibiting cyt-PTP epsilon activity, versus effects by D2 flanking sequences that prevented constitutive dimerization and inactivation [<xref rid="B48-molecules-23-00395" ref-type="bibr">48</xref>]. Likewise, the <italic>DUSP3</italic> gene product, VHR, forms transient homodimers inside cells, resulting in a temporal inactivation of the dual-specificity phosphatase [<xref rid="B49-molecules-23-00395" ref-type="bibr">49</xref>]. In addition, laforin, the Lafora disease-associated PTP that dephosphorylates branched glucose polymers, is able to form dimers or even multimers, but here oligomerisation of the enzyme results in cooperative substrate binding and increased activity [<xref rid="B50-molecules-23-00395" ref-type="bibr">50</xref>]. The PTEN tumor suppressor&#8217;s phosphatase activity on PI(3,4,5)P<sub>3</sub> also depends on dimerization (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>C), which requires its C-terminal tail to be unphosphorylated [<xref rid="B51-molecules-23-00395" ref-type="bibr">51</xref>,<xref rid="B52-molecules-23-00395" ref-type="bibr">52</xref>]. Likewise, for the myotubularin-related (MTMR) 14-member subfamily of PTPs, enzyme activity towards phosphoinositides is regulated via homo- and hetero-dimer formation (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>H). MTMR2, for example, requires the formation of membrane-associated dimers to exert its role in PI(3,5)P<sub>2</sub> and PI(3)P turnover [<xref rid="B53-molecules-23-00395" ref-type="bibr">53</xref>]. Phosphatase-inactive MTMR9 is able to increase enzymatic activity, and even substrate specificity, of MTMR6 and MTMR8 via heterodimerization [<xref rid="B54-molecules-23-00395" ref-type="bibr">54</xref>,<xref rid="B55-molecules-23-00395" ref-type="bibr">55</xref>]. Finally, the phosphatase of regenerating liver (PRL) phosphatases, that are able to stimulate ERK1/2 and Akt signaling and are overexpressed in many cancer types [<xref rid="B56-molecules-23-00395" ref-type="bibr">56</xref>], also depend on oligomerization for their activity. Here, not dimers but trimers represent the active conformation of the enzymes (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>D). In line with this, a small compound, termed Cmpd-43, that prevented PRL1 trimer formation indeed successfully abrogated the enzyme&#8217;s activity [<xref rid="B57-molecules-23-00395" ref-type="bibr">57</xref>].</p></sec><sec id="sec2dot3-molecules-23-00395"><title>2.3. Regulating Anchoring and Scaffolding Activity of PTPs</title><p>Although the paradigm activity of PTPs is the dephosphorylation of proteins&#8212;or of other biomolecules including phosphoinositides [<xref rid="B58-molecules-23-00395" ref-type="bibr">58</xref>], glycogens and even RNA&#8212;several PTP family members are catalytically inactive [<xref rid="B6-molecules-23-00395" ref-type="bibr">6</xref>]. As observed for the MTMR subfamily, such inactive representatives are well capable of regulating the activities of other PTPs. In addition, RPTP ligands serve as examples of proteins that modulate PTP activity by means of protein&#8211;protein interactions. However, there are additional PTP binders that need to be introduced here. Proteins harboring so-called PDZ (PSD-95, Dlg, ZO-1) domains have demonstrated unprecedented powers in orchestrating submembranous signaling complexes [<xref rid="B59-molecules-23-00395" ref-type="bibr">59</xref>] and in doing so they regulate the stability and activity of transmembrane receptors (e.g., [<xref rid="B60-molecules-23-00395" ref-type="bibr">60</xref>]) as well as cytoplasmic proteins. For example, amyloid-beta aggregates, which lead to synaptic toxicity and cognitive dysfunction in Alzheimer&#8217;s disease, initiate the recruitment of PTEN to the postsynaptic area in brain cells. This PTEN relocation was dependent of its C-terminal PDZ target site (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>J), as demonstrated by the use of a cell-permeable interfering peptide [<xref rid="B61-molecules-23-00395" ref-type="bibr">61</xref>]. Remarkably, non-peptidic small molecules mimicking PDZ-binding motifs are proficient to inhibit the interaction of PTEN with PDZ domains [<xref rid="B62-molecules-23-00395" ref-type="bibr">62</xref>,<xref rid="B63-molecules-23-00395" ref-type="bibr">63</xref>], indicating their potential as scaffolds for therapeutic drug development.</p><p>In a study showing how syndecan-4 (SD4) is able to down-regulate T-cell receptor (TCR)-mediated signals coming from the immune synapse, again a crucial contribution of PDZ domain-mediated interactions was disclosed [<xref rid="B64-molecules-23-00395" ref-type="bibr">64</xref>]. The immune receptor SD4 is expressed on activated T-cells and its C-terminus is permanently bound by one of syntenin&#8217;s tandem PDZ domains. Upon ligand binding to SD4, syntenin additionally binds to and activates CD148 [<xref rid="B64-molecules-23-00395" ref-type="bibr">64</xref>], a receptor-type PTP encoded by gene <italic>PTPRJ</italic> (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>I), likely through a second PDZ domain mediated interaction [<xref rid="B65-molecules-23-00395" ref-type="bibr">65</xref>]. Another fine example comes from PTPN4, a cytosolic PTP that consists of an N-terminal FERM domain, a middle segment harboring a single PDZ domain, and C-terminally the catalytic PTP domain (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>G). PTPN4 normally protects cells from apoptosis but addition of ligands for the PTPN4 PDZ domain resulted in a marked induction of cell death [<xref rid="B66-molecules-23-00395" ref-type="bibr">66</xref>]. Subsequent studies revealed that the PTPN4 PDZ domain in fact auto-inhibits the enzyme&#8217;s catalytic activity, and this is abrogated upon binding of a PDZ domain ligand [<xref rid="B67-molecules-23-00395" ref-type="bibr">67</xref>,<xref rid="B68-molecules-23-00395" ref-type="bibr">68</xref>]. The segment linking the PDZ and PTP domain in PTPN4 is also contributing to this regulatory principle [<xref rid="B69-molecules-23-00395" ref-type="bibr">69</xref>,<xref rid="B70-molecules-23-00395" ref-type="bibr">70</xref>]. Thus, possibilities to interfere with PDZ-mediated PPIs represent novel routes to correct disease-related signaling processes.</p></sec></sec><sec id="sec3-molecules-23-00395"><title>3. Expanding the Druggable Genome Using Proteinaceous Drugs</title><p>From the above, the picture emerges that novel possibilities to modulate PTP activities can be envisioned when focus is redirected from the catalytic core towards enzyme parts that are involved in regulatory PPIs. For long, the field has been reluctant towards the development of drugs that would interfere with PPIs but slowly the tide is turning [<xref rid="B71-molecules-23-00395" ref-type="bibr">71</xref>,<xref rid="B72-molecules-23-00395" ref-type="bibr">72</xref>]. For example, venetoclax, a drug that prevents the anti-apoptotic BCL-2 protein to interact with pro-apoptotic BAX and BAK, has successfully entered the clinic for treatment of lymphoid malignancies [<xref rid="B73-molecules-23-00395" ref-type="bibr">73</xref>]. We already mentioned small compound PPI inhibitors that successfully inactivate SHP2 and PRL1 by targeting intra- and intermolecular interactions, respectively [<xref rid="B24-molecules-23-00395" ref-type="bibr">24</xref>,<xref rid="B25-molecules-23-00395" ref-type="bibr">25</xref>,<xref rid="B57-molecules-23-00395" ref-type="bibr">57</xref>], and thus opt for potential cancer therapeutics [<xref rid="B74-molecules-23-00395" ref-type="bibr">74</xref>]. Not surprisingly, also PDZ-mediated interactions gained quite some attention as potential drug targets for PPI inhibitor design. Based on the C-terminal peptide sequence from one of the ligands for the human AF6 (ALL1-fused gene from chromosome 6) PDZ domain, for example, high-affinity small compounds have been produced that inhibit AF6-Bcr interactions and interfere with growth factor signaling in leukemia cells [<xref rid="B75-molecules-23-00395" ref-type="bibr">75</xref>]. Furthermore, compounds ZL006 and IC87201, identified as efficient inhibitors of the PDZ-based nNOS/PSD-95 interaction, are being considered as promising drugs to treat ischemic stroke and pain [<xref rid="B76-molecules-23-00395" ref-type="bibr">76</xref>]. Confining ourselves to PTPs as drug targets, the findings from studies on idiopathic pulmonary fibrosis come to mind [<xref rid="B77-molecules-23-00395" ref-type="bibr">77</xref>] which led to the patenting of a small molecule that blocks the PDZ-mediated association of PTPN13 with the C-terminus of FAS (US Patent Application 20120148528; Published international patent WO/2012/064763).</p><p>Given that the protein surfaces involved in PPIs are usually much larger than the catalytic pockets targeted by small molecule inhibitors, this novel playground holds great promise for larger, protein-based compounds (<xref ref-type="fig" rid="molecules-23-00395-f003">Figure 3</xref>). Although for intracellular PPI targets the design of small molecule inhibitors is more obvious in view of delivery, PPI inhibitor discovery for extracellular interactions is also open for proteinaceous approaches [<xref rid="B78-molecules-23-00395" ref-type="bibr">78</xref>]. These include antibody-based and protein- and peptide-display library strategies [<xref rid="B79-molecules-23-00395" ref-type="bibr">79</xref>] and resulting tools are then indicated with names like single-chain variable fragments, darpins, monobodies or foldamers. In addition, peptide- and peptidomimetics-based PPIs are explored. As opposed to small chemical therapeutics, the development of such proteinaceous drugs faces distinct challenges regarding immunogenicity, proteolytic sensitivity and tissue and cell penetrability, but promising developments in these areas are penetrating the literature. We will briefly introduce the basics underlying these protein-based tools before turning to their applications within the PTP field.</p><p>The most obvious approach to design a PPI inhibitor, i.e., pick a peptide sequence derived from the interface of the target PPI, actually appears quite effective despite the fact that relevant 3D protein structures&#8212;let alone spatial information on the protein&#8211;protein interactions themselves&#8212;are usually lacking. Homology modeling and dynamic calculations may help realize a computational design. Alternatively, a functional approach such as display library screening could serve in yielding a peptide starting point [<xref rid="B72-molecules-23-00395" ref-type="bibr">72</xref>,<xref rid="B78-molecules-23-00395" ref-type="bibr">78</xref>]. The next hurdle is then impinged by the alleged folding structure; does the peptide reflect an alpha-helix, a beta hairpin or rather a coiled segment? Quite often protein interaction interfaces involve alpha-helical structures [<xref rid="B80-molecules-23-00395" ref-type="bibr">80</xref>] but since there is a large entropic penalty for binding, a stabilization of peptide structures seems mandatory. Unmodified peptides in isolation appear poor inhibitors, and the success of peptide display screening strategies mirrors just that; peptides are then presented within a protein domain context. Researchers have therefore explored possibilities to stabilize peptide segments through modifications, usually cyclization or stapling [<xref rid="B81-molecules-23-00395" ref-type="bibr">81</xref>]. In addition, the synthesis of peptide-like molecules that mimic protein structural segments, carrying names like peptoids or foldamers, and display improved biostability and cell permeability is being pursued [<xref rid="B82-molecules-23-00395" ref-type="bibr">82</xref>,<xref rid="B83-molecules-23-00395" ref-type="bibr">83</xref>]. Especially the possibility to conjugate peptides or peptidomimetics with other molecules opens new avenues for peptide therapeutics development. Dozens of peptide conjugates are currently being evaluated in clinical trials. The combination of a peptide component and a chemotherapeutic agent, for example, may ensure targeted delivery at the relevant site, merging improved safety and higher dosing of the anticancer agent [<xref rid="B84-molecules-23-00395" ref-type="bibr">84</xref>]. As structural information on PPIs and the chemist&#8217;s toolbox to produce peptidomimetics are expanding [<xref rid="B85-molecules-23-00395" ref-type="bibr">85</xref>], it is a matter of time before such compounds make up a considerable part of the peptide therapeutics that enter the clinic [<xref rid="B86-molecules-23-00395" ref-type="bibr">86</xref>,<xref rid="B87-molecules-23-00395" ref-type="bibr">87</xref>].</p><p>Zooming out from peptide(-like) molecules that modulate PPIs (<xref ref-type="fig" rid="molecules-23-00395-f003">Figure 3</xref>A&#8211;C), the next option would be to turn to larger peptide scaffolds (of some 20&#8211;50 amino acid residues), protein domains or even whole proteins. After all one could view such larger structures as composed of two distinct regions; a core scaffold fused to a bioactive peptide sequence or peptide-binding structure (<xref ref-type="fig" rid="molecules-23-00395-f003">Figure 3</xref>D&#8211;F). Many different examples have been described in the literature, ranging from decoy receptors that abrogate ligand&#8211;receptor binding [<xref rid="B88-molecules-23-00395" ref-type="bibr">88</xref>] to antibody-derived fragments such as immunoglobin Fc domains [<xref rid="B89-molecules-23-00395" ref-type="bibr">89</xref>] or single-chain variable fragments (scFvs) [<xref rid="B90-molecules-23-00395" ref-type="bibr">90</xref>]. Decoy receptors result from proteolytic cleavage of genuine receptors and/or alternative splicing of receptor-encoding transcripts [<xref rid="B88-molecules-23-00395" ref-type="bibr">88</xref>] and are of interest because of their non-immunogenicity in humans. Immunoglobulin-derived molecules make up a major part of the current-day biologics used in the clinic [<xref rid="B91-molecules-23-00395" ref-type="bibr">91</xref>], but also many non-immunoglobulin-based protein domains and scaffolds, such as monobodies [<xref rid="B92-molecules-23-00395" ref-type="bibr">92</xref>] and darpins [<xref rid="B93-molecules-23-00395" ref-type="bibr">93</xref>], have been explored in the search for specific, stable and bioactive binding modules that target proteins [<xref rid="B91-molecules-23-00395" ref-type="bibr">91</xref>,<xref rid="B92-molecules-23-00395" ref-type="bibr">92</xref>]. Some of these tools are indeed exploited to develop PTP inhibitors, as described below. </p></sec><sec id="sec4-molecules-23-00395"><title>4. Towards Proteinaceous Drugs that Regulate Protein Tyrosine Phosphatases</title><p>Ever since the notion that receptor-type PTP dimerization alters their enzymatic activity [<xref rid="B40-molecules-23-00395" ref-type="bibr">40</xref>] the impact of compounds that bind to the extracellular, ligand-binding segment became of interest as tools to boost or inhibit RPTPs. Bona fide RPTP ligands have hardly been identified [<xref rid="B44-molecules-23-00395" ref-type="bibr">44</xref>] but the paradigm example of pleiotrophin, that upon binding abrogates PTPRZ-B activity through dimerization [<xref rid="B45-molecules-23-00395" ref-type="bibr">45</xref>,<xref rid="B46-molecules-23-00395" ref-type="bibr">46</xref>], underscores the potential. In line, antibodies that bind to RPTPs on the cell surface indeed are able to regulate their function (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>A). A recent example comes from work from the Tremblay group that investigated the possibility to modulate RPTP&#963; activity using previously identified ligands and novel monoclonal antibodies [<xref rid="B94-molecules-23-00395" ref-type="bibr">94</xref>]. On cells, RPTP&#963; present as dimers in a manner that is independent of the intracellular wedge domain and rather results from extracellular homotypic interactions [<xref rid="B95-molecules-23-00395" ref-type="bibr">95</xref>,<xref rid="B96-molecules-23-00395" ref-type="bibr">96</xref>]. Intriguingly, two ligands of RPTP&#963;&#8212;chondroitin sulfate and heparan sulfate proteoglycans (CSPGs and HSPGs)&#8212;compete for binding to the same Ig-like domain in the RPTP&#963; extracellular part but induce opposing effects; CSPGs prevent dimerization and HSPGs facilitate RPTP&#963; dimer formation [<xref rid="B97-molecules-23-00395" ref-type="bibr">97</xref>,<xref rid="B98-molecules-23-00395" ref-type="bibr">98</xref>]. A similar type of opposing regulation by proteoglycans had been noted previously for <italic>Drosophila</italic> LAR [<xref rid="B99-molecules-23-00395" ref-type="bibr">99</xref>]. The RPTP&#963;-specific monoclonal antibody 4.5H5 was shown to firmly increase RPTP&#963; dimerization, translating in enhanced neuritogenesis in neurite outgrowth assays [<xref rid="B94-molecules-23-00395" ref-type="bibr">94</xref>]. This provides proof of principle that such dimer-inducing, inactivating anti-RPTP antibodies (see <xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>A) could be turned into biologics, for example for the treatment of patients with spinal cord injuries.</p><p>Antibodies may also be used to prevent PTP oligomerization. The notion that trimer formation is required for PRL enzymatic activity [<xref rid="B57-molecules-23-00395" ref-type="bibr">57</xref>] suggests the possibility to design antibodies that would prevent PRL trimer formation. Although anti-PRL antibodies have been generated and proved valuable tools to treat PRL over-expressing cancers in preclinical settings [<xref rid="B100-molecules-23-00395" ref-type="bibr">100</xref>,<xref rid="B101-molecules-23-00395" ref-type="bibr">101</xref>,<xref rid="B102-molecules-23-00395" ref-type="bibr">102</xref>], their mechanism of action is not preventing PRL trimers to form but rather mounting an efficient and specific antibody-mediated immune response against this intracellular oncotarget. As an alternative approach to prevent PTP oligomerization the exploitation of a decoy receptor has been reported [<xref rid="B103-molecules-23-00395" ref-type="bibr">103</xref>]. In joint-lining synoviocytes, that in rheumatoid arthritis are responsible for joint inflammation and destruction of cartilage and bone, the HSPG syndecan-4 (SD4) constitutively interacts with&#8212;and clusters and inactivates&#8212;RPTP&#963;. Disruption of this interaction could be achieved by the extracellular provision of competing amounts of the ligand-binding RPTP&#963; Ig-like domain part, unleashing its intracellular enzyme activity. With this set-up, synoviocyte invasiveness and cartilage attachment was impaired, and established arthritis could be reversed in rheumatoid arthritis models [<xref rid="B103-molecules-23-00395" ref-type="bibr">103</xref>].</p><p>Takahashi and coworkers generated a monoclonal antibody against the CD148 ectodomain on endothelial cells and demonstrated that it effectively blocked angiogenesis in mice. Contrary to what one might expect, this was not due to dimerization-induced inactivation of the RPTP, but rather an increased CD148 activity was noted [<xref rid="B104-molecules-23-00395" ref-type="bibr">104</xref>]. Building on screening results from a combinatorial phage display library, Trapasso&#8217;s group optimized cyclic nonapeptides that bind to the CD148 ectodomain. These ligand mimetics had a high tendency to dimerize and were found to also activate the phosphatase [<xref rid="B105-molecules-23-00395" ref-type="bibr">105</xref>]. Thus, RPTP oligomerization may impact differently on the catalytic activity depending on the individual components in the complex and the rotational coupling imposed upon the cytoplasmic moieties. This had been noted also in experiments addressing possible redox regulation of RPTP&#945; dimers [<xref rid="B106-molecules-23-00395" ref-type="bibr">106</xref>]. This redox sensitivity of PTP enzymes, observed as a local and transient PTP inactivation due to reactive oxygen species production that parallels growth factor signaling [<xref rid="B19-molecules-23-00395" ref-type="bibr">19</xref>], actually allowed the development of a unique type of PTP biotherapeutic. The Tonks lab applied phage display technology to select a single-chain variable fragment, scFv45, that would specifically bind to the reversibly oxidized, sulfenyl-amide intermediate form of PTP1B that is catalytically inactive (PTP1B-OX) [<xref rid="B107-molecules-23-00395" ref-type="bibr">107</xref>]. They hypothesized that such a conformation-specific antibody may stabilize the inactive state and thus inhibit PTP1B activity (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>B). Using the conformation sensor scFv45 as &#8220;intrabody&#8221; indeed an attenuation of PTP1B activity in response to insulin-induced reactive oxygen species production and concomitant increased insulin receptor-dependent signaling was obtained [<xref rid="B107-molecules-23-00395" ref-type="bibr">107</xref>], providing an alternative route to design PTP-specific inhibitors.</p><p>In addition, non-antibody scaffolds have been used to merge combinatorial library designs and selection strategies in order to isolate synthetic proteins that bind their targets with affinities and specificities that compare well to those of antibodies but come with advantages such as small size and lack of disulfide bonds [<xref rid="B92-molecules-23-00395" ref-type="bibr">92</xref>]. A nice illustration comes from work on SHP2, the proto-oncogenic SH2 domain-containing cytosolic PTP that has been in the limelight as a drug target for quite a while [<xref rid="B23-molecules-23-00395" ref-type="bibr">23</xref>] but again enzyme inhibitor development was frustrated by the conserved nature of the PTP domain [<xref rid="B74-molecules-23-00395" ref-type="bibr">74</xref>]. Some years back, Sha et al. realized that also the SH2 domains in SHP2 pose a specificity problem due to their highly homologous nature [<xref rid="B108-molecules-23-00395" ref-type="bibr">108</xref>]. Building on their success to generate highly specific monobodies, i.e., synthetic &#946;-sandwich proteins based on the human fibronectin type III domain framework, that bind the BCR-ABL SH2 domain they screened for monobodies that would target the tandem SHP2 SH2 domains (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>C). Indeed they obtained a set of tools that, when expressed in leukemic cells, differentially inhibit distinct roles of SHP2 in downstream signaling events, such as paxillin and STAT5 phosphorylation, depending on whether they competed with phosphotyrosine binding to the first or the second SH2 domain in SHP2 [<xref rid="B108-molecules-23-00395" ref-type="bibr">108</xref>].</p><p>As mentioned, small-molecule inhibitor development for PTP1B had been frustrated due to the extreme resemblance of the active site in the paralogous T-cell PTP (TCPTP) [<xref rid="B109-molecules-23-00395" ref-type="bibr">109</xref>]. Since the latter is linked to the development of multiple inflammatory diseases, therapeutic agents that selectively inhibit TCPTP would also be highly welcomed. Pei and coworkers took up the challenge to derive cell-permeable bicyclic peptidyl inhibitors for these closely related PTPs [<xref rid="B110-molecules-23-00395" ref-type="bibr">110</xref>,<xref rid="B111-molecules-23-00395" ref-type="bibr">111</xref>]. Their approach features a short L-2-naphthylalanine-containing cell-penetrating peptide in one ring and a target-binding peptide in the second (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>B). They constructed a library of beads, with a complexity of 0.5 million, that each carried a random pentapeptide sequence with, on position 2, a phosphotyrosine mimic, and, on the other four positions, any amino acid out of a mixture of 10 proteinogenic and 5 unnatural l-amino acids, and 9 d-amino acids. Using PTP1B as bait for some 300,000 beads, 65 binders were identified and individually sequenced. Subsequent optimization resulted in a cell-permeable bicyclic peptidyl inhibitor for PTP1B (KD = 37 nM) that displayed a 17-fold selectivity over TCPTP [<xref rid="B111-molecules-23-00395" ref-type="bibr">111</xref>]. Next, along similar lines, they mined for TCPTP-specific inhibitors. This time around one million compounds were affinity purified in two sequential rounds, yielding 137 positive beads. Following several optimization steps, the final bicyclic peptide inhibitor for TCPTP (IC<sub>50</sub> = 110 nM) displayed effectiveness in EGF-stimulated C6 glioma cells but with only four-fold selectivity over PTP1B [<xref rid="B110-molecules-23-00395" ref-type="bibr">110</xref>]. Overall, encouraging results that place the option of bicyclic peptides that combine cell-penetrating and target inhibiting characteristics as a potential strategy to produce PTP-regulatory compounds. However, current small-molecule inhibitors for these closely related PTPs appear much more potent and selective, and have even entered clinical trials [<xref rid="B18-molecules-23-00395" ref-type="bibr">18</xref>].</p><p>Expanding on examples of peptide-based drugs, we return to the impact of the wedge domain on dimerization-regulated activity in a subset of receptor-type PTPs. Studies with RPTP&#945; and CD45 had shown that such helix-loop-helix wedge domains block enzyme activity in RPTP homodimers [<xref rid="B40-molecules-23-00395" ref-type="bibr">40</xref>,<xref rid="B42-molecules-23-00395" ref-type="bibr">42</xref>]. The cell adhesion molecule-like receptor-type PTPs like LAR, RPTP&#181; and RPTP&#963; also contain a wedge domain in between their transmembrane and PTP domains [<xref rid="B34-molecules-23-00395" ref-type="bibr">34</xref>] and &#8220;wedge peptides&#8221; have been designed in an attempt to interfere with RPTP functioning (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>A). Cell-penetrating wedge peptides based on LAR and RPTP&#181; sequences have been tested in the rat PC12 cell model for NGF-induced neurite outgrowth or in retinal ganglion neurons seeded on a RPTP&#181;-exposing substrate, respectively [<xref rid="B112-molecules-23-00395" ref-type="bibr">112</xref>]. Both &#8220;wedge Tat peptides&#8221; effectively and specifically blocked the survival- and neurite-promoting effects linked to their corresponding RPTPs [<xref rid="B112-molecules-23-00395" ref-type="bibr">112</xref>]. Additional support for cell-penetrating wedge domain peptides as PTP inhibiting biologics comes from work on a cell-permeable wedge peptide drug for RPTP&#963;, termed &#8220;intracellular sigma peptide&#8221; (ISP). Silver and coworkers demonstrated its effectiveness in abrogating CSPG-RPTP&#963;-mediated inhibition of axonal regrowth and sprouting, hence facilitating functional recovery, in a spinal cord injury model [<xref rid="B113-molecules-23-00395" ref-type="bibr">113</xref>]. Since CSPGs present in the cardiac scar after a myocardial infarction prevent sympathetic re-innervation by activating RPTP&#963;, they also studied the effects of daily injections of ISP in mice that experienced an experimentally induced infarction several days earlier. Application of the wedge peptide indeed restored sympathetic innervation, and the resulting infarcted hearts were electrically indistinguishable from un-infarcted hearts and resistant to induced arrhythmias [<xref rid="B114-molecules-23-00395" ref-type="bibr">114</xref>]. In addition, in an animal model for severe nerve root injury, systemic delivery of ISP clearly enhanced nerve regeneration, firmly corroborating the therapeutic potential of this RPTP&#963;-specific cell-penetrating wedge peptide [<xref rid="B115-molecules-23-00395" ref-type="bibr">115</xref>].</p><p>There is one particular regulatory part in PTPs that has not been discussed as a target of proteinaceous drugs, and that is the carboxyl-terminal region (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>D). In a recent review [<xref rid="B116-molecules-23-00395" ref-type="bibr">116</xref>] Elson and colleagues have compiled evidence that cytosolic tails of receptor-type PTPs are exploited in various ways for regulating phosphatase activity. Likewise, there is ample evidence that C-termini of cytosolic PTPs are impacting on enzyme behavior as well. This may reflect the PTP&#8217;s subcellular localization, as for e.g., PTP1B [<xref rid="B117-molecules-23-00395" ref-type="bibr">117</xref>], but mostly these boil down to the protein&#8211;protein interactions mediated by so-called PDZ domains [<xref rid="B118-molecules-23-00395" ref-type="bibr">118</xref>]. C-terminal PDZ domain binding sites have been noted in a considerable percentage of the RPTPs [<xref rid="B116-molecules-23-00395" ref-type="bibr">116</xref>], but also in non-receptor PTPs like e.g., PTEN [<xref rid="B119-molecules-23-00395" ref-type="bibr">119</xref>] such PPI-mediating C-termini are present. Adding to the complexity, several PTP family members (PTPN3, PTPN4, PTPN13 and PTPN20) actually contain PDZ domains themselves, shaping an extensive PPI network in control of reversible phosphotyrosine signaling in health and disease (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E). The PDZ domain-regulated impact of PTPN4 on glioblastoma cell survival [<xref rid="B66-molecules-23-00395" ref-type="bibr">66</xref>] points to the modulation of PDZ-dependent PPIs as an attractive cancer treatment option. </p></sec><sec id="sec5-molecules-23-00395"><title>5. Untying Gordian Knots in Glioblastomas</title><p>Glioblastomas are brain tumors characterized by diffuse infiltrative growth in the surrounding parenchyma. Conventional therapeutic strategies combine surgical resection, radiotherapy and temozolomide chemotherapy [<xref rid="B120-molecules-23-00395" ref-type="bibr">120</xref>] but as yet it remains impossible to cure patients, urging the need for increased knowledge on disease etiology to formulate novel therapeutic options. Some years back, we reviewed a list of PTP genes that bear links to gliomagenesis [<xref rid="B121-molecules-23-00395" ref-type="bibr">121</xref>]. More recently, we classified a subset of PTPs as possible entry points for glioma treatment based on a comparison of their relative expression levels in normal and tumor brain material combined with expression and survival data from relevant databases [<xref rid="B122-molecules-23-00395" ref-type="bibr">122</xref>]. Three of these genes (<italic>PTPRZ1</italic>, <italic>PTEN</italic>, <italic>PTPRT</italic>) encode PTPs with C-terminal PDZ binding motifs [<xref rid="B116-molecules-23-00395" ref-type="bibr">116</xref>,<xref rid="B123-molecules-23-00395" ref-type="bibr">123</xref>] and mapping of the interacting PDZ domain-containing proteins may be of relevance for glioblastoma etiology. </p><p><italic>PTPRZ1</italic> encodes three protein isoforms that share an N-terminal, extracellular carbonic anhydrase-like (CAH) and a fibronectin type III (FNIII) domain [<xref rid="B124-molecules-23-00395" ref-type="bibr">124</xref>]. <italic>PTPRZ1</italic> expression, notably of the receptor-type PTPRZ-B isoform, is up-regulated in gliomas and several studies have underscored that down-regulation of PTPRZ-B reduces glioblastoma growth in in vivo models [<xref rid="B125-molecules-23-00395" ref-type="bibr">125</xref>,<xref rid="B126-molecules-23-00395" ref-type="bibr">126</xref>,<xref rid="B127-molecules-23-00395" ref-type="bibr">127</xref>]. A peptide derived from PTPRZ-B&#8217;s extracellular moiety now forms part of a peptide-based glioma vaccine called IMA950 [<xref rid="B128-molecules-23-00395" ref-type="bibr">128</xref>] that is currently in phase I/II clinical trials. Historically, a first in vivo attempt to therapeutically exploit PTPRZ overexpression in glioma dates back to 2006 when a saporin-coupled antibody against the PTPRZ-B extracellular domain was found to significantly delay human U87 glioma tumor growth in a subcutaneous mouse xenograft model [<xref rid="B126-molecules-23-00395" ref-type="bibr">126</xref>]. The most recent endeavor reflects the development and testing of SCB4830, a small inhibitory compound that specifically targets the PTPRZ-B catalytic site [<xref rid="B127-molecules-23-00395" ref-type="bibr">127</xref>]. Here, C6 glioblastoma cells had been transplanted into rat brains and the inhibitor was applied as a liposome complex by means of daily intracerebroventricular injections to find a reduction in tumor growth. </p><p>While studying the role of PTPRZ-B in glioblastoma proliferation and migration we noted that its extracellular part is mediating migratory signals whereas the proliferative effect is exerted by the intracellular part [<xref rid="B125-molecules-23-00395" ref-type="bibr">125</xref>]. More specially, the PTPRZ-B C-terminal PDZ binding motif appeared crucial for the latter process, and thus two PDZ domain-containing partners of PTPRZ-B need introduction: PSD95 and MAGI-2 (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E). PSD95 contains three PDZ domains of which the second binds to the PTPRZ-B C-terminus [<xref rid="B129-molecules-23-00395" ref-type="bibr">129</xref>]. Using either its first or second PDZ domain PSD95 can also bind to ErbB4, a member of the broadly expressed family of epidermal growth factor receptor-type tyrosine kinases that impact on cell proliferation, survival and migration [<xref rid="B130-molecules-23-00395" ref-type="bibr">130</xref>]. Thus, PSD95 can bind both proteins simultaneously, facilitating the dephosphorylation of ErbB4 by PTPRZ-B, but it can also facilitate ErbB4 homo-dimerization and subsequent auto-activation [<xref rid="B131-molecules-23-00395" ref-type="bibr">131</xref>]. PDZ proteins thus may regulate phosphotyrosine-mediated signals through the organization of RTK/RPTP clusters. It also implies that changes in the expression of components participating in such regulatory clusters will have consequences. High PTPRZ-B levels, as in glioblastoma cells, thus may lead to decreased ErbB4 activity in two ways; by sequestering PSD95 and preventing PDZ-mediated ErbB4 homodimer formation as well as by directly dephosphorylating ErbB4. Unlike for its family member ErbB1 (EGFR), reduced ErbB4 activity rather facilitates proliferation, survival and differentiation of brain tissue (reviewed in [<xref rid="B132-molecules-23-00395" ref-type="bibr">132</xref>]). It is tempting to speculate that the high PTPRZ-B levels in glioma, as part of their tumor-promoting effect, hamper ErbB4-mediated inhibition of proliferation. Proteinacious compounds that specifically block PDZ interactions have been derived, and these might prove beneficial in treating glioma. For instance, the peptide that blocks PDZ1 and PDZ2 in PSD95 [<xref rid="B133-molecules-23-00395" ref-type="bibr">133</xref>] may disrupt the interaction with PTPRZ-B and affect glioblastoma cell proliferation.</p><p>PTPRZ-B and ErbB4 can also be bound by PDZ domains in the submembranous anchoring proteins MAGI-1, MAGI-2 and MAGI-3 [<xref rid="B134-molecules-23-00395" ref-type="bibr">134</xref>]. MAGI-based ErbB4/PTPRZ-B complexes may serve similar purposes as described above for PSD95 (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E). Alternatively, PSD95 and MAGI could compete for binding to ErbB4 and PTPRZ-B and redirect them to different subcellular signaling niches. In addition, MAGI-1 serves as a PTPRZ-B substrate [<xref rid="B135-molecules-23-00395" ref-type="bibr">135</xref>]. MAGI-3 is not a substrate itself but as a scaffold it provides PTPRZ-B access to phosphoproteins like p130 in glioma cells [<xref rid="B136-molecules-23-00395" ref-type="bibr">136</xref>]. Likewise, MAGI-1 may facilitate &#946;-catenin dephosphorylation by PTPRZ-B [<xref rid="B45-molecules-23-00395" ref-type="bibr">45</xref>] through the recruitment of substrate and enzyme using its fifth and second PDZ domain, respectively [<xref rid="B46-molecules-23-00395" ref-type="bibr">46</xref>,<xref rid="B137-molecules-23-00395" ref-type="bibr">137</xref>] (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E). Of note, &#946;-catenin levels are often upregulated in cancers and tyrosine-phosphorylated &#946;-catenin increases Wnt signaling and tumorigenesis [<xref rid="B138-molecules-23-00395" ref-type="bibr">138</xref>]. Since increased PTPRZ-B levels in the presence of abundant MAGI-1 should result in &#946;-catenin dephosphorylation, hence tumor suppression, we reason that the MAGI&#8211;&#946;-catenin link is unable to downplay PTPRZ-B&#8217;s tumorigenic role in glioma.</p><p>There are many more proteins that bind to PTPRZ-B [<xref rid="B139-molecules-23-00395" ref-type="bibr">139</xref>] and in databases like BioGrid, String and InAct currently 138 are mentioned. This would provide a tremendous puzzle on how to keep PPI-disrupting compounds both targeted and effective. We found experimental evidence (our unpublished data) for yet another PTPRZ-B interacting protein, PTPN13 (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E). The handful of PDZ domains in this large submembranous protein enable PTPN13 to bind a wide range of proteins [<xref rid="B140-molecules-23-00395" ref-type="bibr">140</xref>]. For example, PTPN13 PDZ domains bind the carboxyl-terminal &#8220;SLV&#8221; sequence in the programmed cell death receptor FAS [<xref rid="B141-molecules-23-00395" ref-type="bibr">141</xref>]. In addition, PTPRZ-B ends in the &#8220;SLV&#8221; PDZ target sequence [<xref rid="B116-molecules-23-00395" ref-type="bibr">116</xref>]. PTPN13 thus contributes to endocytosis and degradation of FAS, increasing cell resistance to apoptosis [<xref rid="B141-molecules-23-00395" ref-type="bibr">141</xref>]. Conversely, cells with high autophagic activity degrade PTPN13 and become sensitive to FAS induced apoptosis [<xref rid="B142-molecules-23-00395" ref-type="bibr">142</xref>]. In line, application of an &#8220;SLV&#8221; tripeptide or the functionally equivalent small molecule Quinobene in human CD34+ chronic myeloid leukemia cells increased their FAS sensitivity [<xref rid="B143-molecules-23-00395" ref-type="bibr">143</xref>]. PTPN13 is an enigmatic player in the cancer field, displaying both oncogenic as well as tumor suppressive functions depending on tumor context [<xref rid="B140-molecules-23-00395" ref-type="bibr">140</xref>]. For example, disruptive PTPN13 mutations have been found in various tumor samples [<xref rid="B144-molecules-23-00395" ref-type="bibr">144</xref>,<xref rid="B145-molecules-23-00395" ref-type="bibr">145</xref>] including HPV-negative head and neck squamous cell carcinomas [<xref rid="B146-molecules-23-00395" ref-type="bibr">146</xref>]. In contrast, oncogenic functions for PTPN13 are suggested by an EWS-FLI1 chromosomal translocation in Ewing&#8217;s sarcoma that leads to a strong up-regulation of PTPN13 protein levels, thereby boosting cell growth and motility [<xref rid="B147-molecules-23-00395" ref-type="bibr">147</xref>]. As mentioned above, PTPN13 facilitates resistance to apoptosis via the control of FAS cell surface levels (reviewed in [<xref rid="B140-molecules-23-00395" ref-type="bibr">140</xref>]). Whether and how the PTPN13&#8211;PTPRZ-B interaction contributes to gliomagenesis remains to be investigated. Intriguingly, in a glioblastoma cell model we reproducibly observed high levels of cell death and additionally massive and rapid cell fusions upon PTPN13 shRNA-mediated knock-down (our unpublished data). This is not seen following depletion of PTPRZ-B [<xref rid="B125-molecules-23-00395" ref-type="bibr">125</xref>]. The speed at which cell fusions occur rules out that the underlying mechanism reflects PTPN13&#8217;s contribution to cytokinesis [<xref rid="B148-molecules-23-00395" ref-type="bibr">148</xref>]. The resulting large cell fusions rather are reminiscent of the rare Giant Cell Glioblastoma subtype [<xref rid="B149-molecules-23-00395" ref-type="bibr">149</xref>] that is characterized by giant cells containing multiple nuclei [<xref rid="B150-molecules-23-00395" ref-type="bibr">150</xref>]. Independent of its potential to bind to the PTPRZ-B C-terminus, it will be worthwhile to examine PTPN13 levels in Giant Cell Glioblastoma samples. </p><p>About one-third of the glioblastomas carry inactivating mutations in the gene encoding PTEN. Interestingly, the PTEN C-terminus (&#8220;TKV&#8221;) is bound by many of the same PDZ domain-containing proteins that bind to PTPRZ-B (<xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>E), including PSD95, MAGI-1 and PTPN13 [<xref rid="B123-molecules-23-00395" ref-type="bibr">123</xref>]. In a recent study on conserved potential synthetic lethal gene pairs (meaning that inactivation of one of the genes in the pair will not kill the cell because the other will compensate, but inhibiting both genes does kill the cell) the combination <italic>PTPRZ1</italic>&#8211;<italic>PTEN</italic> was amongst the 20% most likely predictions [<xref rid="B151-molecules-23-00395" ref-type="bibr">151</xref>]. Although <italic>PTEN</italic> and <italic>PTPRZ1</italic> are cancer modulating genes in their own right, this synthetic lethal hypothesis sheds more light on the occurrence of PTEN deletion and PTPRZ-B upregulation within glioma specimens. Since PTEN and PTPRZ-B at least in part share their PDZ domain-mediated interactome, altered expression of one will modify hardwiring of the other PTP. PDZ domain-mediated PTEN recruitment to the cell membrane allows a more efficient dephosphorylation of phospholipids (<xref ref-type="fig" rid="molecules-23-00395-f002">Figure 2</xref>J and <xref ref-type="fig" rid="molecules-23-00395-f004">Figure 4</xref>D) [<xref rid="B152-molecules-23-00395" ref-type="bibr">152</xref>]. PTPRZ-B on the other hand already resides at the cell membrane and, although it can affect AKT through Fyn [<xref rid="B153-molecules-23-00395" ref-type="bibr">153</xref>], it may also impact on the PI3K pathway by keeping PTEN from its PDZ-based anchoring spots. This may well involve PTPN13. In addition, for the PDZ target sequence (&#8220;SSF&#8221;; [<xref rid="B116-molecules-23-00395" ref-type="bibr">116</xref>]) in the glioblastoma-relevant PTPRT [<xref rid="B122-molecules-23-00395" ref-type="bibr">122</xref>] knowledge on the glioblastoma PDZ interactome could provide new therapeutic avenues. </p><p>However, there are more PDZ-based interactions that hold promise of proteinaceous drug development to treat glioblastomas. Recently, a bidentate molecule (113B7) that prevents the syntenin PDZ domain from binding targets like mutant EGFR (EGFRvIII) was shown to increase radiosensitivity and decrease growth of glioma tumors in vivo [<xref rid="B154-molecules-23-00395" ref-type="bibr">154</xref>]. Then, there is the example of PTPN4, of which the enzyme activity is autoinhibited by its PDZ domain [<xref rid="B67-molecules-23-00395" ref-type="bibr">67</xref>,<xref rid="B68-molecules-23-00395" ref-type="bibr">68</xref>,<xref rid="B69-molecules-23-00395" ref-type="bibr">69</xref>,<xref rid="B70-molecules-23-00395" ref-type="bibr">70</xref>]. Upon ligand binding, the PDZ-mediated inhibition is released and PTPN4 no longer protects glioblastoma cells from apoptosis [<xref rid="B66-molecules-23-00395" ref-type="bibr">66</xref>]. Given the poor prognosis that glioblastoma patients await, and considering that for decades no major treatment improvements could be heralded, one can only hope that drugs targeting specific PDZ-mediated PPIs will rapidly enter the clinic. Furthermore, having viral proteins that bind via their C-terminus to PDZ domain-containing PTP family members &#8212;such as the oncogenic HPV E6 [<xref rid="B146-molecules-23-00395" ref-type="bibr">146</xref>,<xref rid="B155-molecules-23-00395" ref-type="bibr">155</xref>]&#8212;to interfere with cellular functions, the application of cell-penetrating PDZ-binding peptides may also have bearing for the treatment of HPV-positive cancers [<xref rid="B156-molecules-23-00395" ref-type="bibr">156</xref>].</p></sec><sec id="sec6-molecules-23-00395"><title>6. Conclusions and Perspectives</title><p>For decades, PTP enzymes have been reluctant to attempts to specifically interfere with their functioning. Increased knowledge on their contributions to diseases and on the regulatory principles that govern their actions is now aiding the removal of their stigma of being undruggable. We argue that, apart from initiatives to specifically target the catalytic PTP domains, strategies that aim at protein interactions mediated by these enzymes, notably&#8212;but not solely&#8212;PDZ domain-based interactions, provide appealing routes to modify PTP functioning. </p><p>Of course, there are many hurdles. Especially when dealing with PPIs, one should realize that any post-translational modification, including phosphorylation, may alter binding specificities of target proteins or their partners. Furthermore, PPI inhibitors are of the competitive type, meaning that bioavailability and the reaching of the required dosage in target tissues represent tremendous challenges. Finally, in view of the complex interaction networks built by the plethora of biomolecules in cells, the targeting of protein&#8211;protein interactions inevitably will mean that the displaced components may then associate with promiscuous other interacting partners, with potential novel complications. On the other hand, by drugging just a single specific interaction in a target protein&#8217;s complex social network, one may cut off negative effects attributed to that single interaction while leaving remaining, beneficial interactions untouched. The current, massive studies towards protein&#8211;protein interactions and protein regulatory mechanisms will fuel these attempts to expand the toolbox to regulate and correct protein behavior, including that of the protein tyrosine phosphatase enzyme family. High hopes are on antibody-type biologicals that bind to and act via the extracellular portion of receptor-type PTPs and on cell-penetrating peptide-like compounds that specifically interfere with intracellular PTP-protein interactions.</p></sec></body><back><ack><title>Acknowledgments</title><p>This article is in commemoration of Jan T.G. Schepens (deceased 11 March 2017), who dedicated most of his working life to the cell biological role of PTPs. His talent and wit are sadly missed. The work was supported in part by a Marie Curie Research Training Network grant (PTPNET/MRTN-CT-2006-035830), a UMC St Radboud research grant (R0000761; The Netherlands), and grant SAF2016-79847-R from Ministerio de Econom&#237;a y Competitividad (Spain and Fondo Europeo de Desarrollo Regional). R.P. is supported by IKERBASQUE, Basque Foundation for Science (Basque Country, Spain).</p></ack><notes><title>Author Contributions</title><p>W.H., W.L. and R.P. supervised the project. A.B. and W.H. prepared figures and references and wrote a first concept. W.L. and R.P. revised the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-molecules-23-00395"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>P.</given-names></name></person-group><article-title>Protein kinases&#8212;The major drug targets of the twenty-first century?</article-title><source>Nat. Rev. Drug Discov.</source><year>2002</year><volume>1</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/nrd773</pub-id><?supplied-pmid 12120283?><pub-id pub-id-type="pmid">12120282</pub-id></element-citation></ref><ref id="B2-molecules-23-00395"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>W.J.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities</article-title><source>Biochim. Biophys. Acta</source><year>2013</year><volume>1832</volume><fpage>1673</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2013.05.022</pub-id><?supplied-pmid 23707412?><pub-id pub-id-type="pmid">23707412</pub-id></element-citation></ref><ref id="B3-molecules-23-00395"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>W.J.</given-names></name><name><surname>Elson</surname><given-names>A.</given-names></name><name><surname>Harroch</surname><given-names>S.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name><name><surname>Stoker</surname><given-names>A.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name></person-group><article-title>Protein tyrosine phosphatases in health and disease</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>708</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1111/febs.12000</pub-id><?supplied-pmid 22938156?><pub-id pub-id-type="pmid">22938156</pub-id></element-citation></ref><ref id="B4-molecules-23-00395"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>R.</given-names></name><name><surname>Neel</surname><given-names>B.G.</given-names></name><name><surname>Rapoport</surname><given-names>T.A.</given-names></name></person-group><article-title>Mathematical models of protein kinase signal transduction</article-title><source>Mol. Cell</source><year>2002</year><volume>9</volume><fpage>957</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00528-2</pub-id><pub-id pub-id-type="pmid">12049733</pub-id></element-citation></ref><ref id="B5-molecules-23-00395"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornberg</surname><given-names>J.J.</given-names></name><name><surname>Bruggeman</surname><given-names>F.J.</given-names></name><name><surname>Binder</surname><given-names>B.</given-names></name><name><surname>Geest</surname><given-names>C.R.</given-names></name><name><surname>de Vaate</surname><given-names>A.J.</given-names></name><name><surname>Lankelma</surname><given-names>J.</given-names></name><name><surname>Heinrich</surname><given-names>R.</given-names></name><name><surname>Westerhoff</surname><given-names>H.V.</given-names></name></person-group><article-title>Principles behind the multifarious control of signal transduction. Erk phosphorylation and kinase/phosphatase control</article-title><source>FEBS J.</source><year>2005</year><volume>272</volume><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.2004.04404.x</pub-id><?supplied-pmid 15634347?><pub-id pub-id-type="pmid">15634347</pub-id></element-citation></ref><ref id="B6-molecules-23-00395"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>The extended human ptpome: A growing tyrosine phosphatase family</article-title><source>FEBS J.</source><year>2016</year><volume>283</volume><fpage>1404</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1111/febs.13600</pub-id><?supplied-pmid 26573778?><pub-id pub-id-type="pmid">26573778</pub-id></element-citation></ref><ref id="B7-molecules-23-00395"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barford</surname><given-names>D.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Tonks</surname><given-names>N.K.</given-names></name></person-group><article-title>Protein tyrosine phosphatases take off</article-title><source>Nat. Struct. Biol.</source><year>1995</year><volume>2</volume><fpage>1043</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1038/nsb1295-1043</pub-id><?supplied-pmid 8846213?><pub-id pub-id-type="pmid">8846213</pub-id></element-citation></ref><ref id="B8-molecules-23-00395"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>J.N.</given-names></name><name><surname>Mortensen</surname><given-names>O.H.</given-names></name><name><surname>Peters</surname><given-names>G.H.</given-names></name><name><surname>Drake</surname><given-names>P.G.</given-names></name><name><surname>Iversen</surname><given-names>L.F.</given-names></name><name><surname>Olsen</surname><given-names>O.H.</given-names></name><name><surname>Jansen</surname><given-names>P.G.</given-names></name><name><surname>Andersen</surname><given-names>H.S.</given-names></name><name><surname>Tonks</surname><given-names>N.K.</given-names></name><name><surname>Moller</surname><given-names>N.P.</given-names></name></person-group><article-title>Structural and evolutionary relationships among protein tyrosine phosphatase domains</article-title><source>Mol. Cell. Biol.</source><year>2001</year><volume>21</volume><fpage>7117</fpage><lpage>7136</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.21.7117-7136.2001</pub-id><?supplied-pmid 11585896?><pub-id pub-id-type="pmid">11585896</pub-id></element-citation></ref><ref id="B9-molecules-23-00395"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>R.J.</given-names></name><name><surname>Yu</surname><given-names>Z.H.</given-names></name><name><surname>Zhang</surname><given-names>R.Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Protein tyrosine phosphatases as potential therapeutic targets</article-title><source>Acta Pharmacol. Sin.</source><year>2014</year><volume>35</volume><fpage>1227</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1038/aps.2014.80</pub-id><?supplied-pmid 25220640?><pub-id pub-id-type="pmid">25220640</pub-id></element-citation></ref><ref id="B10-molecules-23-00395"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peti</surname><given-names>W.</given-names></name><name><surname>Page</surname><given-names>R.</given-names></name></person-group><article-title>Strategies to make protein serine/threonine (pp1, calcineurin) and tyrosine phosphatases (ptp1b) druggable: Achieving specificity by targeting substrate and regulatory protein interaction sites</article-title><source>Bioorg. Med. Chem.</source><year>2015</year><volume>23</volume><fpage>2781</fpage><lpage>2785</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.02.040</pub-id><?supplied-pmid 25771485?><pub-id pub-id-type="pmid">25771485</pub-id></element-citation></ref><ref id="B11-molecules-23-00395"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>A.L.</given-names></name><name><surname>Groom</surname><given-names>C.R.</given-names></name></person-group><article-title>The druggable genome</article-title><source>Nat. Rev. Drug Discov.</source><year>2002</year><volume>1</volume><fpage>727</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1038/nrd892</pub-id><?supplied-pmid 12209152?><pub-id pub-id-type="pmid">12209152</pub-id></element-citation></ref><ref id="B12-molecules-23-00395"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanford</surname><given-names>S.M.</given-names></name><name><surname>Bottini</surname><given-names>N.</given-names></name></person-group><article-title>Targeting tyrosine phosphatases: Time to end the stigma</article-title><source>Trends Pharmacol. Sci.</source><year>2017</year><volume>38</volume><fpage>524</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.03.004</pub-id><?supplied-pmid 28412041?><pub-id pub-id-type="pmid">28412041</pub-id></element-citation></ref><ref id="B13-molecules-23-00395"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elchebly</surname><given-names>M.</given-names></name><name><surname>Payette</surname><given-names>P.</given-names></name><name><surname>Michaliszyn</surname><given-names>E.</given-names></name><name><surname>Cromlish</surname><given-names>W.</given-names></name><name><surname>Collins</surname><given-names>S.</given-names></name><name><surname>Loy</surname><given-names>A.L.</given-names></name><name><surname>Normandin</surname><given-names>D.</given-names></name><name><surname>Cheng</surname><given-names>A.</given-names></name><name><surname>Himms-Hagen</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1b gene</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>1544</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1126/science.283.5407.1544</pub-id><?supplied-pmid 10066179?><pub-id pub-id-type="pmid">10066179</pub-id></element-citation></ref><ref id="B14-molecules-23-00395"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaman</surname><given-names>L.D.</given-names></name><name><surname>Boss</surname><given-names>O.</given-names></name><name><surname>Peroni</surname><given-names>O.D.</given-names></name><name><surname>Kim</surname><given-names>J.K.</given-names></name><name><surname>Martino</surname><given-names>J.L.</given-names></name><name><surname>Zabolotny</surname><given-names>J.M.</given-names></name><name><surname>Moghal</surname><given-names>N.</given-names></name><name><surname>Lubkin</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>Y.B.</given-names></name><name><surname>Sharpe</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1b-deficient mice</article-title><source>Mol. Cell. Biol.</source><year>2000</year><volume>20</volume><fpage>5479</fpage><lpage>5489</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.15.5479-5489.2000</pub-id><?supplied-pmid 10891488?><pub-id pub-id-type="pmid">10891488</pub-id></element-citation></ref><ref id="B15-molecules-23-00395"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tartaglia</surname><given-names>M.</given-names></name><name><surname>Niemeyer</surname><given-names>C.M.</given-names></name><name><surname>Fragale</surname><given-names>A.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Buechner</surname><given-names>J.</given-names></name><name><surname>Jung</surname><given-names>A.</given-names></name><name><surname>Hahlen</surname><given-names>K.</given-names></name><name><surname>Hasle</surname><given-names>H.</given-names></name><name><surname>Licht</surname><given-names>J.D.</given-names></name><name><surname>Gelb</surname><given-names>B.D.</given-names></name></person-group><article-title>Somatic mutations in ptpn11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</article-title><source>Nat. Genet.</source><year>2003</year><volume>34</volume><fpage>148</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/ng1156</pub-id><?supplied-pmid 12717436?><pub-id pub-id-type="pmid">12717436</pub-id></element-citation></ref><ref id="B16-molecules-23-00395"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinker</surname><given-names>B.A.</given-names></name><name><surname>Rondinone</surname><given-names>C.M.</given-names></name><name><surname>Trevillyan</surname><given-names>J.M.</given-names></name><name><surname>Gum</surname><given-names>R.J.</given-names></name><name><surname>Clampit</surname><given-names>J.E.</given-names></name><name><surname>Waring</surname><given-names>J.F.</given-names></name><name><surname>Xie</surname><given-names>N.</given-names></name><name><surname>Wilcox</surname><given-names>D.</given-names></name><name><surname>Jacobson</surname><given-names>P.</given-names></name><name><surname>Frost</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Ptp1b antisense oligonucleotide lowers ptp1b protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>11357</fpage><lpage>11362</lpage><pub-id pub-id-type="doi">10.1073/pnas.142298199</pub-id><?supplied-pmid 12169659?><pub-id pub-id-type="pmid">12169659</pub-id></element-citation></ref><ref id="B17-molecules-23-00395"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>S.K.</given-names></name><name><surname>Yu</surname><given-names>X.X.</given-names></name><name><surname>Watts</surname><given-names>L.M.</given-names></name><name><surname>Michael</surname><given-names>M.D.</given-names></name><name><surname>Sloop</surname><given-names>K.W.</given-names></name><name><surname>Rivard</surname><given-names>A.R.</given-names></name><name><surname>Leedom</surname><given-names>T.A.</given-names></name><name><surname>Manchem</surname><given-names>V.P.</given-names></name><name><surname>Samadzadeh</surname><given-names>L.</given-names></name><name><surname>McKay</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>14291</fpage><lpage>14299</lpage><pub-id pub-id-type="doi">10.1074/jbc.M609626200</pub-id><?supplied-pmid 17353188?><pub-id pub-id-type="pmid">17353188</pub-id></element-citation></ref><ref id="B18-molecules-23-00395"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollu</surname><given-names>L.R.</given-names></name><name><surname>Mazumdar</surname><given-names>A.</given-names></name><name><surname>Savage</surname><given-names>M.I.</given-names></name><name><surname>Brown</surname><given-names>P.H.</given-names></name></person-group><article-title>Molecular pathways: Targeting protein tyrosine phosphatases in cancer</article-title><source>Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>2136</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0934</pub-id><?supplied-pmid 28087641?><pub-id pub-id-type="pmid">28087641</pub-id></element-citation></ref><ref id="B19-molecules-23-00395"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostman</surname><given-names>A.</given-names></name><name><surname>Frijhoff</surname><given-names>J.</given-names></name><name><surname>Sandin</surname><given-names>A.</given-names></name><name><surname>Bohmer</surname><given-names>F.D.</given-names></name></person-group><article-title>Regulation of protein tyrosine phosphatases by reversible oxidation</article-title><source>J. Biochem.</source><year>2011</year><volume>150</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1093/jb/mvr104</pub-id><?supplied-pmid 21856739?><pub-id pub-id-type="pmid">21856739</pub-id></element-citation></ref><ref id="B20-molecules-23-00395"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>Pten: A yin-yang master regulator protein in health and disease</article-title><source>Methods</source><year>2015</year><volume>77&#8211;78</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2015.02.009</pub-id><?supplied-pmid 25843297?><pub-id pub-id-type="pmid">25843297</pub-id></element-citation></ref><ref id="B21-molecules-23-00395"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>S.Q.</given-names></name><name><surname>Ouyang</surname><given-names>M.</given-names></name><name><surname>Brandmaier</surname><given-names>A.</given-names></name><name><surname>Hao</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>W.H.</given-names></name></person-group><article-title>Pten in the maintenance of genome integrity: From DNA replication to chromosome segregation</article-title><source>BioEssays: News Rev. Mol. Cell. Dev. Biol.</source><year>2017</year><volume>39</volume><pub-id pub-id-type="doi">10.1002/bies.201700082</pub-id><?supplied-pmid 28891157?><pub-id pub-id-type="pmid">28891157</pub-id></element-citation></ref><ref id="B22-molecules-23-00395"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barford</surname><given-names>D.</given-names></name><name><surname>Neel</surname><given-names>B.G.</given-names></name></person-group><article-title>Revealing mechanisms for sh2 domain mediated regulation of the protein tyrosine phosphatase shp-2</article-title><source>Structure</source><year>1998</year><volume>6</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/S0969-2126(98)00027-6</pub-id><pub-id pub-id-type="pmid">9551546</pub-id></element-citation></ref><ref id="B23-molecules-23-00395"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>G.</given-names></name><name><surname>Kalaitzidis</surname><given-names>D.</given-names></name><name><surname>Neel</surname><given-names>B.G.</given-names></name></person-group><article-title>The tyrosine phosphatase shp2 (ptpn11) in cancer</article-title><source>Cancer Metastasis Rev.</source><year>2008</year><volume>27</volume><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s10555-008-9126-y</pub-id><?supplied-pmid 18286234?><pub-id pub-id-type="pmid">18286234</pub-id></element-citation></ref><ref id="B24-molecules-23-00395"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.N.</given-names></name><name><surname>LaMarche</surname><given-names>M.J.</given-names></name><name><surname>Chan</surname><given-names>H.M.</given-names></name><name><surname>Fekkes</surname><given-names>P.</given-names></name><name><surname>Garcia-Fortanet</surname><given-names>J.</given-names></name><name><surname>Acker</surname><given-names>M.G.</given-names></name><name><surname>Antonakos</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Cooke</surname><given-names>V.G.</given-names></name><etal/></person-group><article-title>Allosteric inhibition of shp2 phosphatase inhibits cancers driven by receptor tyrosine kinases</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1038/nature18621</pub-id><?supplied-pmid 27362227?><pub-id pub-id-type="pmid">27362227</pub-id></element-citation></ref><ref id="B25-molecules-23-00395"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia Fortanet</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>Y.N.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Firestone</surname><given-names>B.</given-names></name><name><surname>Fekkes</surname><given-names>P.</given-names></name><name><surname>Fodor</surname><given-names>M.</given-names></name><name><surname>Fortin</surname><given-names>P.D.</given-names></name><name><surname>Fridrich</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Allosteric inhibition of shp2: Identification of a potent, selective, and orally efficacious phosphatase inhibitor</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>7773</fpage><lpage>7782</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00680</pub-id><?supplied-pmid 27347692?><pub-id pub-id-type="pmid">27347692</pub-id></element-citation></ref><ref id="B26-molecules-23-00395"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Si</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Allosteric inhibitors of shp2 with therapeutic potential for cancer treatment</article-title><source>J. Med. Chem.</source><fpage>2017</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01520</pub-id><?supplied-pmid 29155585?><pub-id pub-id-type="pmid">29155585</pub-id></element-citation></ref><ref id="B27-molecules-23-00395"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes-Xavier</surname><given-names>C.</given-names></name><name><surname>Roma-Mateo</surname><given-names>C.</given-names></name><name><surname>Rios</surname><given-names>P.</given-names></name><name><surname>Tarrega</surname><given-names>C.</given-names></name><name><surname>Cejudo-Marin</surname><given-names>R.</given-names></name><name><surname>Tabernero</surname><given-names>L.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>Dual-specificity map kinase phosphatases as targets of cancer treatment</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2011</year><volume>11</volume><fpage>109</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.2174/187152011794941190</pub-id></element-citation></ref><ref id="B28-molecules-23-00395"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camps</surname><given-names>M.</given-names></name><name><surname>Nichols</surname><given-names>A.</given-names></name><name><surname>Gillieron</surname><given-names>C.</given-names></name><name><surname>Antonsson</surname><given-names>B.</given-names></name><name><surname>Muda</surname><given-names>M.</given-names></name><name><surname>Chabert</surname><given-names>C.</given-names></name><name><surname>Boschert</surname><given-names>U.</given-names></name><name><surname>Arkinstall</surname><given-names>S.</given-names></name></person-group><article-title>Catalytic activation of the phosphatase mkp-3 by erk2 mitogen-activated protein kinase</article-title><source>Science</source><year>1998</year><volume>280</volume><fpage>1262</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1126/science.280.5367.1262</pub-id><?supplied-pmid 9596579?><pub-id pub-id-type="pmid">9596579</pub-id></element-citation></ref><ref id="B29-molecules-23-00395"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>J.P.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Structural basis of docking interactions between erk2 and map kinase phosphatase 3</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>5326</fpage><lpage>5331</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510506103</pub-id><?supplied-pmid 16567630?><pub-id pub-id-type="pmid">16567630</pub-id></element-citation></ref><ref id="B30-molecules-23-00395"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Mapping erk2-mkp3 binding interfaces by hydrogen/deuterium exchange mass spectrometry</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>38834</fpage><lpage>38844</lpage><pub-id pub-id-type="doi">10.1074/jbc.M608916200</pub-id><?supplied-pmid 17046812?><pub-id pub-id-type="pmid">17046812</pub-id></element-citation></ref><ref id="B31-molecules-23-00395"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muda</surname><given-names>M.</given-names></name><name><surname>Theodosiou</surname><given-names>A.</given-names></name><name><surname>Rodrigues</surname><given-names>N.</given-names></name><name><surname>Boschert</surname><given-names>U.</given-names></name><name><surname>Camps</surname><given-names>M.</given-names></name><name><surname>Gillieron</surname><given-names>C.</given-names></name><name><surname>Davies</surname><given-names>K.</given-names></name><name><surname>Ashworth</surname><given-names>A.</given-names></name><name><surname>Arkinstall</surname><given-names>S.</given-names></name></person-group><article-title>The dual specificity phosphatases m3/6 and mkp-3 are highly selective for inactivation of distinct mitogen-activated protein kinases</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>27205</fpage><lpage>27208</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.44.27205</pub-id><?supplied-pmid 8910287?><pub-id pub-id-type="pmid">8910287</pub-id></element-citation></ref><ref id="B32-molecules-23-00395"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaltenmeier</surname><given-names>C.T.</given-names></name><name><surname>Vollmer</surname><given-names>L.L.</given-names></name><name><surname>Vernetti</surname><given-names>L.A.</given-names></name><name><surname>Caprio</surname><given-names>L.</given-names></name><name><surname>Davis</surname><given-names>K.</given-names></name><name><surname>Korotchenko</surname><given-names>V.N.</given-names></name><name><surname>Day</surname><given-names>B.W.</given-names></name><name><surname>Tsang</surname><given-names>M.</given-names></name><name><surname>Hulkower</surname><given-names>K.I.</given-names></name><name><surname>Lotze</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>A tumor cell-selective inhibitor of mitogen-activated protein kinase phosphatases sensitizes breast cancer cells to lymphokine-activated killer cell activity</article-title><source>J. Pharmacol. Exp. Therap.</source><year>2017</year><volume>361</volume><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1124/jpet.116.239756</pub-id><?supplied-pmid 28154014?><pub-id pub-id-type="pmid">28154014</pub-id></element-citation></ref><ref id="B33-molecules-23-00395"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotchenko</surname><given-names>V.N.</given-names></name><name><surname>Saydmohammed</surname><given-names>M.</given-names></name><name><surname>Vollmer</surname><given-names>L.L.</given-names></name><name><surname>Bakan</surname><given-names>A.</given-names></name><name><surname>Sheetz</surname><given-names>K.</given-names></name><name><surname>Debiec</surname><given-names>K.T.</given-names></name><name><surname>Greene</surname><given-names>K.A.</given-names></name><name><surname>Agliori</surname><given-names>C.S.</given-names></name><name><surname>Bahar</surname><given-names>I.</given-names></name><name><surname>Day</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase</article-title><source>ChemBioChem: Eur. J. Chem. Biol.</source><year>2014</year><volume>15</volume><fpage>1436</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1002/cbic.201402000</pub-id><?supplied-pmid 24909879?><pub-id pub-id-type="pmid">24909879</pub-id></element-citation></ref><ref id="B34-molecules-23-00395"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoker</surname><given-names>A.W.</given-names></name></person-group><article-title>Rptps in axons, synapses and neurology</article-title><source>Semin. Cell Dev. Biol.</source><year>2015</year><volume>37</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2014.09.006</pub-id><?supplied-pmid 25234542?><pub-id pub-id-type="pmid">25234542</pub-id></element-citation></ref><ref id="B35-molecules-23-00395"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>L.L.</given-names></name><name><surname>Veeranna</surname><given-names>S.</given-names></name><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Reddy</surname><given-names>C.C.</given-names></name><name><surname>Sowdhamini</surname><given-names>R.</given-names></name><name><surname>Gopal</surname><given-names>B.</given-names></name></person-group><article-title>Modulation of catalytic activity in multi-domain protein tyrosine phosphatases</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e24766</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024766</pub-id><?supplied-pmid 21931847?><pub-id pub-id-type="pmid">21931847</pub-id></element-citation></ref><ref id="B36-molecules-23-00395"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streuli</surname><given-names>M.</given-names></name><name><surname>Krueger</surname><given-names>N.X.</given-names></name><name><surname>Thai</surname><given-names>T.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name></person-group><article-title>Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases lca and lar</article-title><source>EMBO J.</source><year>1990</year><volume>9</volume><fpage>2399</fpage><lpage>2407</lpage><?supplied-pmid 1695146?><pub-id pub-id-type="pmid">1695146</pub-id></element-citation></ref><ref id="B37-molecules-23-00395"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Weiss</surname><given-names>A.</given-names></name></person-group><article-title>Negative regulation of cd45 by differential homodimerization of the alternatively spliced isoforms</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>764</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1038/ni822</pub-id><?supplied-pmid 12134145?><pub-id pub-id-type="pmid">12134145</pub-id></element-citation></ref><ref id="B38-molecules-23-00395"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>G.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name></person-group><article-title>Receptor-like protein tyrosine phosphatase alpha homodimerizes on the cell surface</article-title><source>Mol. Cell. Biol.</source><year>2000</year><volume>20</volume><fpage>5917</fpage><lpage>5929</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.16.5917-5929.2000</pub-id><?supplied-pmid 10913175?><pub-id pub-id-type="pmid">10913175</pub-id></element-citation></ref><ref id="B39-molecules-23-00395"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>S.</given-names></name><name><surname>Blanchetot</surname><given-names>C.</given-names></name><name><surname>Schepens</surname><given-names>J.</given-names></name><name><surname>Albet</surname><given-names>S.</given-names></name><name><surname>Lammers</surname><given-names>R.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name><name><surname>Hendriks</surname><given-names>W.</given-names></name></person-group><article-title>Multimerization of the protein-tyrosine phosphatase (ptp)-like insulin-dependent diabetes mellitus autoantigens ia-2 and ia-2beta with receptor ptps (rptps). Inhibition of rptpalpha enzymatic activity</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>48139</fpage><lpage>48145</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208228200</pub-id><?supplied-pmid 12364328?><pub-id pub-id-type="pmid">12364328</pub-id></element-citation></ref><ref id="B40-molecules-23-00395"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilwes</surname><given-names>A.M.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name><name><surname>Noel</surname><given-names>J.P.</given-names></name></person-group><article-title>Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization</article-title><source>Nature</source><year>1996</year><volume>382</volume><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/382555a0</pub-id><?supplied-pmid 8700232?><pub-id pub-id-type="pmid">8700232</pub-id></element-citation></ref><ref id="B41-molecules-23-00395"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>G.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Noel</surname><given-names>J.</given-names></name><name><surname>Sap</surname><given-names>J.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name></person-group><article-title>Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase-alpha</article-title><source>Nature</source><year>1999</year><volume>401</volume><fpage>606</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1038/44170</pub-id><?supplied-pmid 10524630?><pub-id pub-id-type="pmid">10524630</pub-id></element-citation></ref><ref id="B42-molecules-23-00395"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeti</surname><given-names>R.</given-names></name><name><surname>Bilwes</surname><given-names>A.M.</given-names></name><name><surname>Noel</surname><given-names>J.P.</given-names></name><name><surname>Hunter</surname><given-names>T.</given-names></name><name><surname>Weiss</surname><given-names>A.</given-names></name></person-group><article-title>Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge</article-title><source>Science</source><year>1998</year><volume>279</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1126/science.279.5347.88</pub-id><?supplied-pmid 9417031?><pub-id pub-id-type="pmid">9417031</pub-id></element-citation></ref><ref id="B43-molecules-23-00395"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noordman</surname><given-names>Y.E.</given-names></name><name><surname>Augustus</surname><given-names>E.D.</given-names></name><name><surname>Schepens</surname><given-names>J.T.</given-names></name><name><surname>Chirivi</surname><given-names>R.G.</given-names></name><name><surname>Rios</surname><given-names>P.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name><name><surname>Hendriks</surname><given-names>W.J.</given-names></name></person-group><article-title>Multimerisation of receptor-type protein tyrosine phosphatases ptpbr7 and ptp-sl attenuates enzymatic activity</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1783</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2007.10.023</pub-id><?supplied-pmid 18068678?><pub-id pub-id-type="pmid">18068678</pub-id></element-citation></ref><ref id="B44-molecules-23-00395"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoker</surname><given-names>A.W.</given-names></name></person-group><article-title>Detection and identification of ligands for mammalian rptp extracellular domains</article-title><source>Methods Mol. Biol.</source><year>2016</year><volume>1447</volume><fpage>267</fpage><lpage>281</lpage><?supplied-pmid 27514811?><pub-id pub-id-type="pmid">27514811</pub-id></element-citation></ref><ref id="B45-molecules-23-00395"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>K.</given-names></name><name><surname>Rodriguez-Pena</surname><given-names>A.</given-names></name><name><surname>Dimitrov</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Yamin</surname><given-names>M.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name><name><surname>Deuel</surname><given-names>T.F.</given-names></name></person-group><article-title>Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>2603</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1073/pnas.020487997</pub-id><?supplied-pmid 10706604?><pub-id pub-id-type="pmid">10706604</pub-id></element-citation></ref><ref id="B46-molecules-23-00395"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukada</surname><given-names>M.</given-names></name><name><surname>Fujikawa</surname><given-names>A.</given-names></name><name><surname>Chow</surname><given-names>J.P.</given-names></name><name><surname>Ikematsu</surname><given-names>S.</given-names></name><name><surname>Sakuma</surname><given-names>S.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>Protein tyrosine phosphatase receptor type z is inactivated by ligand-induced oligomerization</article-title><source>FEBS Lett.</source><year>2006</year><volume>580</volume><fpage>4051</fpage><lpage>4056</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.06.041</pub-id><?supplied-pmid 16814777?><pub-id pub-id-type="pmid">16814777</pub-id></element-citation></ref><ref id="B47-molecules-23-00395"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walchli</surname><given-names>S.</given-names></name><name><surname>Espanel</surname><given-names>X.</given-names></name><name><surname>Hooft van Huijsduijnen</surname><given-names>R.</given-names></name></person-group><article-title>Sap-1/ptprh activity is regulated by reversible dimerization</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>331</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.03.196</pub-id><?supplied-pmid 15850787?><pub-id pub-id-type="pmid">15850787</pub-id></element-citation></ref><ref id="B48-molecules-23-00395"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledano-Katchalski</surname><given-names>H.</given-names></name><name><surname>Tiran</surname><given-names>Z.</given-names></name><name><surname>Sines</surname><given-names>T.</given-names></name><name><surname>Shani</surname><given-names>G.</given-names></name><name><surname>Granot-Attas</surname><given-names>S.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name><name><surname>Elson</surname><given-names>A.</given-names></name></person-group><article-title>Dimerization in vivo and inhibition of the nonreceptor form of protein tyrosine phosphatase epsilon</article-title><source>Mol. Cell. Biol.</source><year>2003</year><volume>23</volume><fpage>5460</fpage><lpage>5471</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.15.5460-5471.2003</pub-id><?supplied-pmid 12861030?><pub-id pub-id-type="pmid">12861030</pub-id></element-citation></ref><ref id="B49-molecules-23-00395"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavic</surname><given-names>K.</given-names></name><name><surname>Rios</surname><given-names>P.</given-names></name><name><surname>Dzeyk</surname><given-names>K.</given-names></name><name><surname>Koehler</surname><given-names>C.</given-names></name><name><surname>Lemke</surname><given-names>E.A.</given-names></name><name><surname>Kohn</surname><given-names>M.</given-names></name></person-group><article-title>Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of vhr's phosphatase activity</article-title><source>ACS Chem. Biol.</source><year>2014</year><volume>9</volume><fpage>1451</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1021/cb500240n</pub-id><?supplied-pmid 24798147?><pub-id pub-id-type="pmid">24798147</pub-id></element-citation></ref><ref id="B50-molecules-23-00395"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raththagala</surname><given-names>M.</given-names></name><name><surname>Brewer</surname><given-names>M.K.</given-names></name><name><surname>Parker</surname><given-names>M.W.</given-names></name><name><surname>Sherwood</surname><given-names>A.R.</given-names></name><name><surname>Wong</surname><given-names>B.K.</given-names></name><name><surname>Hsu</surname><given-names>S.</given-names></name><name><surname>Bridges</surname><given-names>T.M.</given-names></name><name><surname>Paasch</surname><given-names>B.C.</given-names></name><name><surname>Hellman</surname><given-names>L.M.</given-names></name><name><surname>Husodo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease</article-title><source>Mol. Cell</source><year>2015</year><volume>57</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.11.020</pub-id><?supplied-pmid 25544560?><pub-id pub-id-type="pmid">25544560</pub-id></element-citation></ref><ref id="B51-molecules-23-00395"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>F.</given-names></name><name><surname>Chakravarthy</surname><given-names>S.</given-names></name><name><surname>Nanda</surname><given-names>H.</given-names></name><name><surname>Papa</surname><given-names>A.</given-names></name><name><surname>Pandolfi</surname><given-names>P.P.</given-names></name><name><surname>Ross</surname><given-names>A.H.</given-names></name><name><surname>Harishchandra</surname><given-names>R.K.</given-names></name><name><surname>Gericke</surname><given-names>A.</given-names></name><name><surname>Losche</surname><given-names>M.</given-names></name></person-group><article-title>The pten tumor suppressor forms homodimers in solution</article-title><source>Structure</source><year>2015</year><volume>23</volume><fpage>1952</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.07.012</pub-id><?supplied-pmid 26299948?><pub-id pub-id-type="pmid">26299948</pub-id></element-citation></ref><ref id="B52-molecules-23-00395"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>A.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Bonora</surname><given-names>M.</given-names></name><name><surname>Salmena</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Hobbs</surname><given-names>R.M.</given-names></name><name><surname>Lunardi</surname><given-names>A.</given-names></name><name><surname>Webster</surname><given-names>K.</given-names></name><name><surname>Ng</surname><given-names>C.</given-names></name><name><surname>Newton</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>Cancer-associated pten mutants act in a dominant-negative manner to suppress pten protein function</article-title><source>Cell</source><year>2014</year><volume>157</volume><fpage>595</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.027</pub-id><?supplied-pmid 24766807?><pub-id pub-id-type="pmid">24766807</pub-id></element-citation></ref><ref id="B53-molecules-23-00395"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>P.</given-names></name><name><surname>Schaffitzel</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>I.</given-names></name><name><surname>Ban</surname><given-names>N.</given-names></name><name><surname>Suter</surname><given-names>U.</given-names></name></person-group><article-title>Membrane association of myotubularin-related protein 2 is mediated by a pleckstrin homology-gram domain and a coiled-coil dimerization module</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>12177</fpage><lpage>12182</lpage><pub-id pub-id-type="doi">10.1073/pnas.2132732100</pub-id><?supplied-pmid 14530412?><pub-id pub-id-type="pmid">14530412</pub-id></element-citation></ref><ref id="B54-molecules-23-00395"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>S.C.</given-names></name><name><surname>Marjanovic</surname><given-names>J.</given-names></name><name><surname>Majerus</surname><given-names>P.W.</given-names></name></person-group><article-title>Mtmr9 increases mtmr6 enzyme activity, stability, and role in apoptosis</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>2064</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1074/jbc.M804292200</pub-id><?supplied-pmid 19038970?><pub-id pub-id-type="pmid">19038970</pub-id></element-citation></ref><ref id="B55-molecules-23-00395"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Marjanovic</surname><given-names>J.</given-names></name><name><surname>Kisseleva</surname><given-names>M.V.</given-names></name><name><surname>Majerus</surname><given-names>P.W.</given-names></name><name><surname>Wilson</surname><given-names>M.P.</given-names></name></person-group><article-title>Myotubularin-related protein (mtmr) 9 determines the enzymatic activity, substrate specificity, and role in autophagy of mtmr8</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>9539</fpage><lpage>9544</lpage><pub-id pub-id-type="doi">10.1073/pnas.1207021109</pub-id><?supplied-pmid 22647598?><pub-id pub-id-type="pmid">22647598</pub-id></element-citation></ref><ref id="B56-molecules-23-00395"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rios</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Kohn</surname><given-names>M.</given-names></name></person-group><article-title>Molecular mechanisms of the prl phosphatases</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>505</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08565.x</pub-id><?supplied-pmid 22413991?><pub-id pub-id-type="pmid">22413991</pub-id></element-citation></ref><ref id="B57-molecules-23-00395"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>Z.H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>R.Y.</given-names></name><name><surname>Zeng</surname><given-names>L.F.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Novel anticancer agents based on targeting the trimer interface of the prl phosphatase</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>4805</fpage><lpage>4815</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2323</pub-id><?supplied-pmid 27325652?><pub-id pub-id-type="pmid">27325652</pub-id></element-citation></ref><ref id="B58-molecules-23-00395"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulido</surname><given-names>R.</given-names></name><name><surname>Stoker</surname><given-names>A.W.</given-names></name><name><surname>Hendriks</surname><given-names>W.J.</given-names></name></person-group><article-title>Ptps emerge as pips: Protein tyrosine phosphatases with lipid-phosphatase activities in human disease</article-title><source>Hum. Mol. Genet.</source><year>2013</year><volume>22</volume><fpage>R66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt347</pub-id><?supplied-pmid 23900072?><pub-id pub-id-type="pmid">23900072</pub-id></element-citation></ref><ref id="B59-molecules-23-00395"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>Z.</given-names></name><name><surname>Lafon</surname><given-names>M.</given-names></name></person-group><article-title>Pdz domain-mediated protein interactions: Therapeutic targets in neurological disorders</article-title><source>Curr. Med. Chem.</source><year>2014</year><volume>21</volume><fpage>2632</fpage><lpage>2641</lpage><pub-id pub-id-type="doi">10.2174/0929867321666140303145312</pub-id><?supplied-pmid 24606518?><pub-id pub-id-type="pmid">24606518</pub-id></element-citation></ref><ref id="B60-molecules-23-00395"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J.</given-names></name><name><surname>VanHouten</surname><given-names>J.N.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Dann</surname><given-names>P.</given-names></name><name><surname>Sullivan</surname><given-names>C.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Sneddon</surname><given-names>W.B.</given-names></name><name><surname>Friedman</surname><given-names>P.A.</given-names></name><name><surname>Wysolmerski</surname><given-names>J.J.</given-names></name></person-group><article-title>The scaffolding protein nherf1 regulates the stability and activity of the tyrosine kinase her2</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>6555</fpage><lpage>6568</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.770883</pub-id><?supplied-pmid 28235801?><pub-id pub-id-type="pmid">28235801</pub-id></element-citation></ref><ref id="B61-molecules-23-00395"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knafo</surname><given-names>S.</given-names></name><name><surname>Sanchez-Puelles</surname><given-names>C.</given-names></name><name><surname>Palomer</surname><given-names>E.</given-names></name><name><surname>Delgado</surname><given-names>I.</given-names></name><name><surname>Draffin</surname><given-names>J.E.</given-names></name><name><surname>Mingo</surname><given-names>J.</given-names></name><name><surname>Wahle</surname><given-names>T.</given-names></name><name><surname>Kaleka</surname><given-names>K.</given-names></name><name><surname>Mou</surname><given-names>L.</given-names></name><name><surname>Pereda-Perez</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Pten recruitment controls synaptic and cognitive function in alzheimer&#8217;s models</article-title><source>Nat. Neurosci.</source><year>2016</year><volume>19</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1038/nn.4225</pub-id><?supplied-pmid 26780512?><pub-id pub-id-type="pmid">26780512</pub-id></element-citation></ref><ref id="B62-molecules-23-00395"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Haresco</surname><given-names>J.J.</given-names></name><name><surname>Novak</surname><given-names>K.A.</given-names></name><name><surname>Stokoe</surname><given-names>D.</given-names></name><name><surname>Kuntz</surname><given-names>I.D.</given-names></name><name><surname>Guy</surname><given-names>R.K.</given-names></name></person-group><article-title>A selective irreversible inhibitor targeting a pdz protein interaction domain</article-title><source>J. Am. Chem. Soc.</source><year>2003</year><volume>125</volume><fpage>12074</fpage><lpage>12075</lpage><pub-id pub-id-type="doi">10.1021/ja035540l</pub-id><?supplied-pmid 14518976?><pub-id pub-id-type="pmid">14518976</pub-id></element-citation></ref><ref id="B63-molecules-23-00395"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>N.</given-names></name><name><surname>Haresco</surname><given-names>J.J.</given-names></name><name><surname>Novak</surname><given-names>K.A.</given-names></name><name><surname>Gage</surname><given-names>R.M.</given-names></name><name><surname>Pedemonte</surname><given-names>N.</given-names></name><name><surname>Stokoe</surname><given-names>D.</given-names></name><name><surname>Kuntz</surname><given-names>I.D.</given-names></name><name><surname>Guy</surname><given-names>R.K.</given-names></name></person-group><article-title>Rational design of a nonpeptide general chemical scaffold for reversible inhibition of pdz domain interactions</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2007</year><volume>17</volume><fpage>549</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2006.10.006</pub-id><?supplied-pmid 17055267?><pub-id pub-id-type="pmid">17055267</pub-id></element-citation></ref><ref id="B64-molecules-23-00395"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J.S.</given-names></name><name><surname>Cruz</surname><given-names>P.D.</given-names><suffix>Jr.</suffix></name><name><surname>Ariizumi</surname><given-names>K.</given-names></name></person-group><article-title>Inhibition of t-cell activation by syndecan-4 is mediated by cd148 through protein tyrosine phosphatase activity</article-title><source>Eur. J. Immunol.</source><year>2011</year><volume>41</volume><fpage>1794</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1002/eji.201041233</pub-id><?supplied-pmid 21469128?><pub-id pub-id-type="pmid">21469128</pub-id></element-citation></ref><ref id="B65-molecules-23-00395"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iuliano</surname><given-names>R.</given-names></name><name><surname>Trapasso</surname><given-names>F.</given-names></name><name><surname>Sama</surname><given-names>I.</given-names></name><name><surname>Le Pera</surname><given-names>I.</given-names></name><name><surname>Martelli</surname><given-names>M.L.</given-names></name><name><surname>Lembo</surname><given-names>F.</given-names></name><name><surname>Santoro</surname><given-names>M.</given-names></name><name><surname>Viglietto</surname><given-names>G.</given-names></name><name><surname>Chiariotti</surname><given-names>L.</given-names></name><name><surname>Fusco</surname><given-names>A.</given-names></name></person-group><article-title>Rat protein tyrosine phosphatase eta physically interacts with the pdz domains of syntenin</article-title><source>FEBS Lett.</source><year>2001</year><volume>500</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(01)02580-7</pub-id><pub-id pub-id-type="pmid">11434923</pub-id></element-citation></ref><ref id="B66-molecules-23-00395"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babault</surname><given-names>N.</given-names></name><name><surname>Cordier</surname><given-names>F.</given-names></name><name><surname>Lafage</surname><given-names>M.</given-names></name><name><surname>Cockburn</surname><given-names>J.</given-names></name><name><surname>Haouz</surname><given-names>A.</given-names></name><name><surname>Prehaud</surname><given-names>C.</given-names></name><name><surname>Rey</surname><given-names>F.A.</given-names></name><name><surname>Delepierre</surname><given-names>M.</given-names></name><name><surname>Buc</surname><given-names>H.</given-names></name><name><surname>Lafon</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Peptides targeting the pdz domain of ptpn4 are efficient inducers of glioblastoma cell death</article-title><source>Structure</source><year>2011</year><volume>19</volume><fpage>1518</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.07.007</pub-id><?supplied-pmid 22000519?><pub-id pub-id-type="pmid">22000519</pub-id></element-citation></ref><ref id="B67-molecules-23-00395"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisonneuve</surname><given-names>P.</given-names></name><name><surname>Caillet-Saguy</surname><given-names>C.</given-names></name><name><surname>Raynal</surname><given-names>B.</given-names></name><name><surname>Gilquin</surname><given-names>B.</given-names></name><name><surname>Chaffotte</surname><given-names>A.</given-names></name><name><surname>Perez</surname><given-names>J.</given-names></name><name><surname>Zinn-Justin</surname><given-names>S.</given-names></name><name><surname>Delepierre</surname><given-names>M.</given-names></name><name><surname>Buc</surname><given-names>H.</given-names></name><name><surname>Cordier</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Regulation of the catalytic activity of the human phosphatase ptpn4 by its pdz domain</article-title><source>FEBS J.</source><year>2014</year><volume>281</volume><fpage>4852</fpage><lpage>4865</lpage><pub-id pub-id-type="doi">10.1111/febs.13024</pub-id><?supplied-pmid 25158884?><pub-id pub-id-type="pmid">25158884</pub-id></element-citation></ref><ref id="B68-molecules-23-00395"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisonneuve</surname><given-names>P.</given-names></name><name><surname>Caillet-Saguy</surname><given-names>C.</given-names></name><name><surname>Vaney</surname><given-names>M.C.</given-names></name><name><surname>Bibi-Zainab</surname><given-names>E.</given-names></name><name><surname>Sawyer</surname><given-names>K.</given-names></name><name><surname>Raynal</surname><given-names>B.</given-names></name><name><surname>Haouz</surname><given-names>A.</given-names></name><name><surname>Delepierre</surname><given-names>M.</given-names></name><name><surname>Lafon</surname><given-names>M.</given-names></name><name><surname>Cordier</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Molecular basis of the interaction of the human protein tyrosine phosphatase non-receptor type 4 (ptpn4) with the mitogen-activated protein kinase p38 gamma</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>16699</fpage><lpage>16708</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.707208</pub-id><?supplied-pmid 27246854?><pub-id pub-id-type="pmid">27246854</pub-id></element-citation></ref><ref id="B69-molecules-23-00395"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caillet-Saguy</surname><given-names>C.</given-names></name><name><surname>Toto</surname><given-names>A.</given-names></name><name><surname>Guerois</surname><given-names>R.</given-names></name><name><surname>Maisonneuve</surname><given-names>P.</given-names></name><name><surname>di Silvio</surname><given-names>E.</given-names></name><name><surname>Sawyer</surname><given-names>K.</given-names></name><name><surname>Gianni</surname><given-names>S.</given-names></name><name><surname>Wolff</surname><given-names>N.</given-names></name></person-group><article-title>Regulation of the human phosphatase ptpn4 by the inter-domain linker connecting the pdz and the phosphatase domains</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>7875</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-08193-6</pub-id><?supplied-pmid 28801650?><pub-id pub-id-type="pmid">28801650</pub-id></element-citation></ref><ref id="B70-molecules-23-00395"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Q.H.</given-names></name><name><surname>Yu</surname><given-names>L.Y.</given-names></name><name><surname>Wang</surname><given-names>S.Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>A.H.</given-names></name><name><surname>Ma</surname><given-names>X.H.</given-names></name><name><surname>Peng</surname><given-names>Y.J.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Structure-based optimization of salt-bridge network across the complex interface of ptpn4 pdz domain with its peptide ligands in neuroglioma</article-title><source>Comput. Biol. Chem.</source><year>2017</year><volume>66</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2016.11.005</pub-id><?supplied-pmid 27923202?><pub-id pub-id-type="pmid">27923202</pub-id></element-citation></ref><ref id="B71-molecules-23-00395"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arkin</surname><given-names>M.R.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Wells</surname><given-names>J.A.</given-names></name></person-group><article-title>Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality</article-title><source>Chem. Biol.</source><year>2014</year><volume>21</volume><fpage>1102</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.09.001</pub-id><?supplied-pmid 25237857?><pub-id pub-id-type="pmid">25237857</pub-id></element-citation></ref><ref id="B72-molecules-23-00395"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>N.</given-names></name><name><surname>Raveh</surname><given-names>B.</given-names></name><name><surname>Schueler-Furman</surname><given-names>O.</given-names></name></person-group><article-title>Druggable protein-protein interactions--from hot spots to hot segments</article-title><source>Curr. Opin. Chem. Biol.</source><year>2013</year><volume>17</volume><fpage>952</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2013.10.011</pub-id><?supplied-pmid 24183815?><pub-id pub-id-type="pmid">24183815</pub-id></element-citation></ref><ref id="B73-molecules-23-00395"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>A.C.</given-names></name><name><surname>Peterson</surname><given-names>T.J.</given-names></name><name><surname>Horvat</surname><given-names>T.Z.</given-names></name><name><surname>Rodriguez</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>L.A.</given-names></name></person-group><article-title>Venetoclax: A first-in-class oral bcl-2 inhibitor for the management of lymphoid malignancies</article-title><source>Ann. Pharmacother.</source><year>2017</year><volume>51</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1177/1060028016685803</pub-id><?supplied-pmid 28056525?><pub-id pub-id-type="pmid">28056525</pub-id></element-citation></ref><ref id="B74-molecules-23-00395"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankson</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>Z.H.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>R.Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Therapeutic targeting of oncogenic tyrosine phosphatases</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>5701</fpage><lpage>5705</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1510</pub-id><?supplied-pmid 28855209?><pub-id pub-id-type="pmid">28855209</pub-id></element-citation></ref><ref id="B75-molecules-23-00395"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>C.</given-names></name><name><surname>Radziwill</surname><given-names>G.</given-names></name><name><surname>Krause</surname><given-names>G.</given-names></name><name><surname>Diehl</surname><given-names>A.</given-names></name><name><surname>Keller</surname><given-names>S.</given-names></name><name><surname>Kamdem</surname><given-names>N.</given-names></name><name><surname>Czekelius</surname><given-names>C.</given-names></name><name><surname>Kreuchwig</surname><given-names>A.</given-names></name><name><surname>Schmieder</surname><given-names>P.</given-names></name><name><surname>Doyle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Small-molecule inhibitors of af6 pdz-mediated protein-protein interactions</article-title><source>ChemMedChem</source><year>2014</year><volume>9</volume><fpage>1458</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201300553</pub-id><?supplied-pmid 24668962?><pub-id pub-id-type="pmid">24668962</pub-id></element-citation></ref><ref id="B76-molecules-23-00395"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>A.</given-names></name><name><surname>Pedersen</surname><given-names>S.W.</given-names></name><name><surname>Dorr</surname><given-names>L.A.</given-names></name><name><surname>Vallon</surname><given-names>G.</given-names></name><name><surname>Ripoche</surname><given-names>I.</given-names></name><name><surname>Ducki</surname><given-names>S.</given-names></name><name><surname>Lian</surname><given-names>L.Y.</given-names></name></person-group><article-title>Biochemical investigations of the mechanism of action of small molecules zl006 and ic87201 as potential inhibitors of the nnos-pdz/psd-95-pdz interactions</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>12157</fpage><pub-id pub-id-type="doi">10.1038/srep12157</pub-id><?supplied-pmid 26177569?><pub-id pub-id-type="pmid">26177569</pub-id></element-citation></ref><ref id="B77-molecules-23-00395"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynes</surname><given-names>M.W.</given-names></name><name><surname>Edelman</surname><given-names>B.L.</given-names></name><name><surname>Kostyk</surname><given-names>A.G.</given-names></name><name><surname>Edwards</surname><given-names>M.G.</given-names></name><name><surname>Coldren</surname><given-names>C.</given-names></name><name><surname>Groshong</surname><given-names>S.D.</given-names></name><name><surname>Cosgrove</surname><given-names>G.P.</given-names></name><name><surname>Redente</surname><given-names>E.F.</given-names></name><name><surname>Bamberg</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>K.K.</given-names></name><etal/></person-group><article-title>Increased cell surface fas expression is necessary and sufficient to sensitize lung fibroblasts to fas ligation-induced apoptosis: Implications for fibroblast accumulation in idiopathic pulmonary fibrosis</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100447</pub-id><?supplied-pmid 21632719?><pub-id pub-id-type="pmid">21632719</pub-id></element-citation></ref><ref id="B78-molecules-23-00395"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laraia</surname><given-names>L.</given-names></name><name><surname>McKenzie</surname><given-names>G.</given-names></name><name><surname>Spring</surname><given-names>D.R.</given-names></name><name><surname>Venkitaraman</surname><given-names>A.R.</given-names></name><name><surname>Huggins</surname><given-names>D.J.</given-names></name></person-group><article-title>Overcoming chemical, biological, and computational challenges in the development of inhibitors targeting protein-protein interactions</article-title><source>Chem. Biol.</source><year>2015</year><volume>22</volume><fpage>689</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2015.04.019</pub-id><?supplied-pmid 26091166?><pub-id pub-id-type="pmid">26091166</pub-id></element-citation></ref><ref id="B79-molecules-23-00395"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathish</surname><given-names>J.G.</given-names></name><name><surname>Sethu</surname><given-names>S.</given-names></name><name><surname>Bielsky</surname><given-names>M.C.</given-names></name><name><surname>de Haan</surname><given-names>L.</given-names></name><name><surname>French</surname><given-names>N.S.</given-names></name><name><surname>Govindappa</surname><given-names>K.</given-names></name><name><surname>Green</surname><given-names>J.</given-names></name><name><surname>Griffiths</surname><given-names>C.E.</given-names></name><name><surname>Holgate</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Challenges and approaches for the development of safer immunomodulatory biologics</article-title><source>Nat. Rev. Drug Discov.</source><year>2013</year><volume>12</volume><fpage>306</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/nrd3974</pub-id><?supplied-pmid 23535934?><pub-id pub-id-type="pmid">23535934</pub-id></element-citation></ref><ref id="B80-molecules-23-00395"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>B.N.</given-names></name><name><surname>Jochim</surname><given-names>A.L.</given-names></name><name><surname>Arora</surname><given-names>P.S.</given-names></name></person-group><article-title>Assessing helical protein interfaces for inhibitor design</article-title><source>J. Am. Chem. Soc.</source><year>2011</year><volume>133</volume><fpage>14220</fpage><lpage>14223</lpage><pub-id pub-id-type="doi">10.1021/ja206074j</pub-id><?supplied-pmid 21846146?><pub-id pub-id-type="pmid">21846146</pub-id></element-citation></ref><ref id="B81-molecules-23-00395"><label>81.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liskamp</surname><given-names>R.M.J.</given-names></name><name><surname>Rijkers</surname><given-names>D.T.S.</given-names></name><name><surname>Bakker</surname><given-names>S.E.</given-names></name></person-group><article-title>Bioactive macrocyclic peptides and peptide mimics</article-title><source>Modern Supramolecular Chemistry</source><publisher-name>Wiley-VCH Verlag GmbH &amp; Co. KGaA</publisher-name><publisher-loc>Weinheim, Germany</publisher-loc><year>2008</year><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="B82-molecules-23-00395"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohm</surname><given-names>M.T.</given-names></name><name><surname>Kapoor</surname><given-names>R.</given-names></name><name><surname>Barron</surname><given-names>A.E.</given-names></name></person-group><article-title>Peptoids: Bio-inspired polymers as potential pharmaceuticals</article-title><source>Curr. Pharm. Des.</source><year>2011</year><volume>17</volume><fpage>2732</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.2174/138161211797416066</pub-id><?supplied-pmid 21728985?><pub-id pub-id-type="pmid">21728985</pub-id></element-citation></ref><ref id="B83-molecules-23-00395"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>C.M.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Shandler</surname><given-names>S.</given-names></name><name><surname>DeGrado</surname><given-names>W.F.</given-names></name></person-group><article-title>Foldamers as versatile frameworks for the design and evolution of function</article-title><source>Nat. Chem. Biol.</source><year>2007</year><volume>3</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nchembio876</pub-id><?supplied-pmid 17438550?><pub-id pub-id-type="pmid">17438550</pub-id></element-citation></ref><ref id="B84-molecules-23-00395"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Accardo</surname><given-names>A.</given-names></name><name><surname>Aloj</surname><given-names>L.</given-names></name><name><surname>Aurilio</surname><given-names>M.</given-names></name><name><surname>Morelli</surname><given-names>G.</given-names></name><name><surname>Tesauro</surname><given-names>D.</given-names></name></person-group><article-title>Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs</article-title><source>Int. J. Nanomed.</source><year>2014</year><volume>9</volume><fpage>1537</fpage><lpage>1557</lpage></element-citation></ref><ref id="B85-molecules-23-00395"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelay-Gimeno</surname><given-names>M.</given-names></name><name><surname>Glas</surname><given-names>A.</given-names></name><name><surname>Koch</surname><given-names>O.</given-names></name><name><surname>Grossmann</surname><given-names>T.N.</given-names></name></person-group><article-title>Structure-based design of inhibitors of protein-protein interactions: Mimicking peptide binding epitopes</article-title><source>Angew. Chem. Int. Ed.</source><year>2015</year><volume>54</volume><fpage>8896</fpage><lpage>8927</lpage><pub-id pub-id-type="doi">10.1002/anie.201412070</pub-id><?supplied-pmid 26119925?><pub-id pub-id-type="pmid">26119925</pub-id></element-citation></ref><ref id="B86-molecules-23-00395"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaspar</surname><given-names>A.A.</given-names></name><name><surname>Reichert</surname><given-names>J.M.</given-names></name></person-group><article-title>Future directions for peptide therapeutics development</article-title><source>Drug Discov. Today</source><year>2013</year><volume>18</volume><fpage>807</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.05.011</pub-id><?supplied-pmid 23726889?><pub-id pub-id-type="pmid">23726889</pub-id></element-citation></ref><ref id="B87-molecules-23-00395"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fosgerau</surname><given-names>K.</given-names></name><name><surname>Hoffmann</surname><given-names>T.</given-names></name></person-group><article-title>Peptide therapeutics: Current status and future directions</article-title><source>Drug Discov. Today</source><year>2015</year><volume>20</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.10.003</pub-id><?supplied-pmid 25450771?><pub-id pub-id-type="pmid">25450771</pub-id></element-citation></ref><ref id="B88-molecules-23-00395"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felix</surname><given-names>J.</given-names></name><name><surname>Savvides</surname><given-names>S.N.</given-names></name></person-group><article-title>Mechanisms of immunomodulation by mammalian and viral decoy receptors: Insights from structures</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>112</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.134</pub-id><?supplied-pmid 28028310?><pub-id pub-id-type="pmid">28028310</pub-id></element-citation></ref><ref id="B89-molecules-23-00395"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czajkowsky</surname><given-names>D.M.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Shao</surname><given-names>Z.</given-names></name><name><surname>Pleass</surname><given-names>R.J.</given-names></name></person-group><article-title>Fc-fusion proteins: New developments and future perspectives</article-title><source>EMBO Mol. Med.</source><year>2012</year><volume>4</volume><fpage>1015</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201379</pub-id><?supplied-pmid 22837174?><pub-id pub-id-type="pmid">22837174</pub-id></element-citation></ref><ref id="B90-molecules-23-00395"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boldicke</surname><given-names>T.</given-names></name></person-group><article-title>Single domain antibodies for the knockdown of cytosolic and nuclear proteins</article-title><source>Protein Sci.: Publ. Protein Soc.</source><year>2017</year><volume>26</volume><fpage>925</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1002/pro.3154</pub-id><?supplied-pmid 28271570?><pub-id pub-id-type="pmid">28271570</pub-id></element-citation></ref><ref id="B91-molecules-23-00395"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohl</surname><given-names>W.R.</given-names></name></person-group><article-title>Current progress in innovative engineered antibodies</article-title><source>Protein Cell</source><year>2017</year><pub-id pub-id-type="doi">10.1007/s13238-017-0457-8</pub-id><?supplied-pmid 28822103?><pub-id pub-id-type="pmid">28822103</pub-id></element-citation></ref><ref id="B92-molecules-23-00395"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>F.</given-names></name><name><surname>Salzman</surname><given-names>G.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Koide</surname><given-names>S.</given-names></name></person-group><article-title>Monobodies and other synthetic binding proteins for expanding protein science</article-title><source>Protein Sci.: Publ. Protein Soc.</source><year>2017</year><volume>26</volume><fpage>910</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1002/pro.3148</pub-id><?supplied-pmid 28249355?><pub-id pub-id-type="pmid">28249355</pub-id></element-citation></ref><ref id="B93-molecules-23-00395"><label>93.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pluckthun</surname><given-names>A.</given-names></name></person-group><article-title>Designed ankyrin repeat proteins (darpins): Binding proteins for research, diagnostics, and therapy</article-title><source>Annual Review of Pharmacology and Toxicology</source><person-group person-group-type="editor"><name><surname>Insel</surname><given-names>P.A.</given-names></name></person-group><publisher-name>ANNUAL REVIEWS</publisher-name><publisher-loc>Palo Alto, CA, USA</publisher-loc><year>2015</year><volume>Volume 55</volume><fpage>489</fpage><lpage>511</lpage></element-citation></ref><ref id="B94-molecules-23-00395"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.L.</given-names></name><name><surname>Hardy</surname><given-names>S.</given-names></name><name><surname>Aubry</surname><given-names>I.</given-names></name><name><surname>Landry</surname><given-names>M.</given-names></name><name><surname>Haggarty</surname><given-names>A.</given-names></name><name><surname>Saragovi</surname><given-names>H.U.</given-names></name><name><surname>Tremblay</surname><given-names>M.L.</given-names></name></person-group><article-title>Identification of function-regulating antibodies targeting the receptor protein tyrosine phosphatase sigma ectodomain</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0178489</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0178489</pub-id><?supplied-pmid 28558026?><pub-id pub-id-type="pmid">28558026</pub-id></element-citation></ref><ref id="B95-molecules-23-00395"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aricescu</surname><given-names>A.R.</given-names></name><name><surname>McKinnell</surname><given-names>I.W.</given-names></name><name><surname>Halfter</surname><given-names>W.</given-names></name><name><surname>Stoker</surname><given-names>A.W.</given-names></name></person-group><article-title>Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma</article-title><source>Mol. Cell. Biol.</source><year>2002</year><volume>22</volume><fpage>1881</fpage><lpage>1892</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.6.1881-1892.2002</pub-id><?supplied-pmid 11865065?><pub-id pub-id-type="pmid">11865065</pub-id></element-citation></ref><ref id="B96-molecules-23-00395"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Faux</surname><given-names>C.</given-names></name><name><surname>Nixon</surname><given-names>J.</given-names></name><name><surname>Alete</surname><given-names>D.</given-names></name><name><surname>Chilton</surname><given-names>J.</given-names></name><name><surname>Hawadle</surname><given-names>M.</given-names></name><name><surname>Stoker</surname><given-names>A.W.</given-names></name></person-group><article-title>Dimerization of protein tyrosine phosphatase sigma governs both ligand binding and isoform specificity</article-title><source>Mol. Cell. Biol.</source><year>2007</year><volume>27</volume><fpage>1795</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1128/MCB.00535-06</pub-id><?supplied-pmid 17178832?><pub-id pub-id-type="pmid">17178832</pub-id></element-citation></ref><ref id="B97-molecules-23-00395"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname><given-names>C.H.</given-names></name><name><surname>Mitakidis</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Elegheert</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Stoker</surname><given-names>A.W.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Craig</surname><given-names>A.M.</given-names></name><name><surname>Jones</surname><given-names>E.Y.</given-names></name><name><surname>Aricescu</surname><given-names>A.R.</given-names></name></person-group><article-title>Structural basis for extracellular cis and trans rptpsigma signal competition in synaptogenesis</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>5209</fpage><pub-id pub-id-type="doi">10.1038/ncomms6209</pub-id><?supplied-pmid 25385546?><pub-id pub-id-type="pmid">25385546</pub-id></element-citation></ref><ref id="B98-molecules-23-00395"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname><given-names>C.H.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Tenney</surname><given-names>A.P.</given-names></name><name><surname>Siebold</surname><given-names>C.</given-names></name><name><surname>Sutton</surname><given-names>G.C.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Gallagher</surname><given-names>J.T.</given-names></name><name><surname>Jones</surname><given-names>E.Y.</given-names></name><name><surname>Flanagan</surname><given-names>J.G.</given-names></name><name><surname>Aricescu</surname><given-names>A.R.</given-names></name></person-group><article-title>Proteoglycan-specific molecular switch for rptpsigma clustering and neuronal extension</article-title><source>Science</source><year>2011</year><volume>332</volume><fpage>484</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1126/science.1200840</pub-id><?supplied-pmid 21454754?><pub-id pub-id-type="pmid">21454754</pub-id></element-citation></ref><ref id="B99-molecules-23-00395"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>K.G.</given-names></name><name><surname>Tenney</surname><given-names>A.P.</given-names></name><name><surname>Ghose</surname><given-names>A.</given-names></name><name><surname>Duckworth</surname><given-names>A.M.</given-names></name><name><surname>Higashi</surname><given-names>M.E.</given-names></name><name><surname>Parfitt</surname><given-names>K.</given-names></name><name><surname>Marcu</surname><given-names>O.</given-names></name><name><surname>Heslip</surname><given-names>T.R.</given-names></name><name><surname>Marsh</surname><given-names>J.L.</given-names></name><name><surname>Schwarz</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>The hspgs syndecan and dallylike bind the receptor phosphatase lar and exert distinct effects on synaptic development</article-title><source>Neuron</source><year>2006</year><volume>49</volume><fpage>517</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2006.01.026</pub-id><?supplied-pmid 16476662?><pub-id pub-id-type="pmid">16476662</pub-id></element-citation></ref><ref id="B100-molecules-23-00395"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thura</surname><given-names>M.</given-names></name><name><surname>Al-Aidaroos</surname><given-names>A.Q.</given-names></name><name><surname>Yong</surname><given-names>W.P.</given-names></name><name><surname>Kono</surname><given-names>K.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>Y.B.</given-names></name><name><surname>Mimura</surname><given-names>K.</given-names></name><name><surname>Thiery</surname><given-names>J.P.</given-names></name><name><surname>Goh</surname><given-names>B.C.</given-names></name><name><surname>Tan</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Prl3-zumab, a first-in-class humanized antibody for cancer therapy</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e87607</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.87607</pub-id><?supplied-pmid 27699276?><pub-id pub-id-type="pmid">27699276</pub-id></element-citation></ref><ref id="B101-molecules-23-00395"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>K.</given-names></name><name><surname>Tang</surname><given-names>J.P.</given-names></name><name><surname>Jie</surname><given-names>L.</given-names></name><name><surname>Al-Aidaroos</surname><given-names>A.Q.</given-names></name><name><surname>Hong</surname><given-names>C.W.</given-names></name><name><surname>Tan</surname><given-names>C.P.</given-names></name><name><surname>Park</surname><given-names>J.E.</given-names></name><name><surname>Varghese</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Engineering the first chimeric antibody in targeting intracellular prl-3 oncoprotein for cancer therapy in mice</article-title><source>Oncotarget</source><year>2012</year><volume>3</volume><fpage>158</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.442</pub-id><?supplied-pmid 22374986?><pub-id pub-id-type="pmid">22374986</pub-id></element-citation></ref><ref id="B102-molecules-23-00395"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>J.P.</given-names></name><name><surname>Tan</surname><given-names>C.P.</given-names></name><name><surname>Hong</surname><given-names>C.W.</given-names></name><name><surname>Al-Aidaroos</surname><given-names>A.Q.</given-names></name><name><surname>Varghese</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name></person-group><article-title>Targeting intracellular oncoproteins with antibody therapy or vaccination</article-title><source>Sci. Transl. Med.</source><year>2011</year><volume>3</volume><fpage>99ra85</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002296</pub-id><?supplied-pmid 21900592?><pub-id pub-id-type="pmid">21900592</pub-id></element-citation></ref><ref id="B103-molecules-23-00395"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>K.M.</given-names></name><name><surname>Stanford</surname><given-names>S.M.</given-names></name><name><surname>Sacchetti</surname><given-names>C.</given-names></name><name><surname>Svensson</surname><given-names>M.N.</given-names></name><name><surname>Coles</surname><given-names>C.H.</given-names></name><name><surname>Mitakidis</surname><given-names>N.</given-names></name><name><surname>Kiosses</surname><given-names>W.B.</given-names></name><name><surname>Bartok</surname><given-names>B.</given-names></name><name><surname>Fos</surname><given-names>C.</given-names></name><name><surname>Cory</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>288ra276</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa4616</pub-id><?supplied-pmid 25995222?><pub-id pub-id-type="pmid">25995222</pub-id></element-citation></ref><ref id="B104-molecules-23-00395"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Mernaugh</surname><given-names>R.L.</given-names></name><name><surname>Tsuboi</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Daniel</surname><given-names>T.O.</given-names></name></person-group><article-title>A monoclonal antibody against cd148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>1234</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-10-4296</pub-id><?supplied-pmid 16597593?><pub-id pub-id-type="pmid">16597593</pub-id></element-citation></ref><ref id="B105-molecules-23-00395"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortuso</surname><given-names>F.</given-names></name><name><surname>Paduano</surname><given-names>F.</given-names></name><name><surname>Carotenuto</surname><given-names>A.</given-names></name><name><surname>Gomez-Monterrey</surname><given-names>I.</given-names></name><name><surname>Bilotta</surname><given-names>A.</given-names></name><name><surname>Gaudio</surname><given-names>E.</given-names></name><name><surname>Sala</surname><given-names>M.</given-names></name><name><surname>Artese</surname><given-names>A.</given-names></name><name><surname>Vernieri</surname><given-names>E.</given-names></name><name><surname>Dattilo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Discovery of ptprj agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation</article-title><source>ACS Chem. Biol.</source><year>2013</year><volume>8</volume><fpage>1497</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1021/cb3007192</pub-id><?supplied-pmid 23627474?><pub-id pub-id-type="pmid">23627474</pub-id></element-citation></ref><ref id="B106-molecules-23-00395"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Wijk</surname><given-names>T.</given-names></name><name><surname>Blanchetot</surname><given-names>C.</given-names></name><name><surname>Overvoorde</surname><given-names>J.</given-names></name><name><surname>den Hertog</surname><given-names>J.</given-names></name></person-group><article-title>Redox-regulated rotational coupling of receptor protein-tyrosine phosphatase alpha dimers</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>13968</fpage><lpage>13974</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300632200</pub-id><?supplied-pmid 12582170?><pub-id pub-id-type="pmid">12582170</pub-id></element-citation></ref><ref id="B107-molecules-23-00395"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haque</surname><given-names>A.</given-names></name><name><surname>Andersen</surname><given-names>J.N.</given-names></name><name><surname>Salmeen</surname><given-names>A.</given-names></name><name><surname>Barford</surname><given-names>D.</given-names></name><name><surname>Tonks</surname><given-names>N.K.</given-names></name></person-group><article-title>Conformation-sensing antibodies stabilize the oxidized form of ptp1b and inhibit its phosphatase activity</article-title><source>Cell</source><year>2011</year><volume>147</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.036</pub-id><?supplied-pmid 21962515?><pub-id pub-id-type="pmid">21962515</pub-id></element-citation></ref><ref id="B108-molecules-23-00395"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>F.</given-names></name><name><surname>Gencer</surname><given-names>E.B.</given-names></name><name><surname>Georgeon</surname><given-names>S.</given-names></name><name><surname>Koide</surname><given-names>A.</given-names></name><name><surname>Yasui</surname><given-names>N.</given-names></name><name><surname>Koide</surname><given-names>S.</given-names></name><name><surname>Hantschel</surname><given-names>O.</given-names></name></person-group><article-title>Dissection of the bcr-abl signaling network using highly specific monobody inhibitors to the shp2 sh2 domains</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>14924</fpage><lpage>14929</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303640110</pub-id><?supplied-pmid 23980151?><pub-id pub-id-type="pmid">23980151</pub-id></element-citation></ref><ref id="B109-molecules-23-00395"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiganis</surname><given-names>T.</given-names></name></person-group><article-title>Ptp1b and tcptp&#8212;Nonredundant phosphatases in insulin signaling and glucose homeostasis</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>445</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08563.x</pub-id><?supplied-pmid 22404968?><pub-id pub-id-type="pmid">22404968</pub-id></element-citation></ref><ref id="B110-molecules-23-00395"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H.</given-names></name><name><surname>Pei</surname><given-names>D.</given-names></name></person-group><article-title>Cell-permeable bicyclic peptidyl inhibitors against t-cell protein tyrosine phosphatase from a combinatorial library</article-title><source>Org. Biomol. Chem.</source><year>2017</year><volume>15</volume><fpage>9595</fpage><lpage>9598</lpage><pub-id pub-id-type="doi">10.1039/C7OB02562A</pub-id><?supplied-pmid 29116277?><pub-id pub-id-type="pmid">29116277</pub-id></element-citation></ref><ref id="B111-molecules-23-00395"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>B.</given-names></name><name><surname>Qian</surname><given-names>Z.</given-names></name><name><surname>Pei</surname><given-names>D.</given-names></name></person-group><article-title>Cell-permeable bicyclic peptide inhibitors against intracellular proteins</article-title><source>J. Am. Chem. Soc.</source><year>2014</year><volume>136</volume><fpage>9830</fpage><lpage>9833</lpage><pub-id pub-id-type="doi">10.1021/ja503710n</pub-id><?supplied-pmid 24972263?><pub-id pub-id-type="pmid">24972263</pub-id></element-citation></ref><ref id="B112-molecules-23-00395"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Massa</surname><given-names>S.M.</given-names></name><name><surname>Ensslen-Craig</surname><given-names>S.E.</given-names></name><name><surname>Major</surname><given-names>D.L.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Tisi</surname><given-names>M.A.</given-names></name><name><surname>Derevyanny</surname><given-names>V.D.</given-names></name><name><surname>Runge</surname><given-names>W.O.</given-names></name><name><surname>Mehta</surname><given-names>B.P.</given-names></name><name><surname>Moore</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Protein-tyrosine phosphatase (ptp) wedge domain peptides: A novel approach for inhibition of ptp function and augmentation of protein-tyrosine kinase function</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>16482</fpage><lpage>16492</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603131200</pub-id><?supplied-pmid 16613844?><pub-id pub-id-type="pmid">16613844</pub-id></element-citation></ref><ref id="B113-molecules-23-00395"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>B.T.</given-names></name><name><surname>Cregg</surname><given-names>J.M.</given-names></name><name><surname>DePaul</surname><given-names>M.A.</given-names></name><name><surname>Tran</surname><given-names>A.P.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Dyck</surname><given-names>S.M.</given-names></name><name><surname>Madalena</surname><given-names>K.M.</given-names></name><name><surname>Brown</surname><given-names>B.P.</given-names></name><name><surname>Weng</surname><given-names>Y.L.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Modulation of the proteoglycan receptor ptpsigma promotes recovery after spinal cord injury</article-title><source>Nature</source><year>2015</year><volume>518</volume><fpage>404</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1038/nature13974</pub-id><?supplied-pmid 25470046?><pub-id pub-id-type="pmid">25470046</pub-id></element-citation></ref><ref id="B114-molecules-23-00395"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>R.T.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Lang</surname><given-names>B.T.</given-names></name><name><surname>Cregg</surname><given-names>J.M.</given-names></name><name><surname>Dunbar</surname><given-names>C.L.</given-names></name><name><surname>Woodward</surname><given-names>W.R.</given-names></name><name><surname>Silver</surname><given-names>J.</given-names></name><name><surname>Ripplinger</surname><given-names>C.M.</given-names></name><name><surname>Habecker</surname><given-names>B.A.</given-names></name></person-group><article-title>Targeting protein tyrosine phosphatase sigma after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6235</fpage><pub-id pub-id-type="doi">10.1038/ncomms7235</pub-id><?supplied-pmid 25639594?><pub-id pub-id-type="pmid">25639594</pub-id></element-citation></ref><ref id="B115-molecules-23-00395"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Ruven</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Lang</surname><given-names>B.T.</given-names></name><name><surname>Silver</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name></person-group><article-title>Enhanced regeneration and functional recovery after spinal root avulsion by manipulation of the proteoglycan receptor ptpsigma</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>14923</fpage><pub-id pub-id-type="doi">10.1038/srep14923</pub-id><?supplied-pmid 26464223?><pub-id pub-id-type="pmid">26464223</pub-id></element-citation></ref><ref id="B116-molecules-23-00395"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnea</surname><given-names>M.</given-names></name><name><surname>Olender</surname><given-names>T.</given-names></name><name><surname>Bedford</surname><given-names>M.T.</given-names></name><name><surname>Elson</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of receptor-type protein tyrosine phosphatases by their c-terminal tail domains</article-title><source>Biochem. Soc. Trans.</source><year>2016</year><volume>44</volume><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1042/BST20160141</pub-id><?supplied-pmid 27911712?><pub-id pub-id-type="pmid">27911712</pub-id></element-citation></ref><ref id="B117-molecules-23-00395"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldhammer</surname><given-names>M.</given-names></name><name><surname>Uetani</surname><given-names>N.</given-names></name><name><surname>Miranda-Saavedra</surname><given-names>D.</given-names></name><name><surname>Tremblay</surname><given-names>M.L.</given-names></name></person-group><article-title>Ptp1b: A simple enzyme for a complex world</article-title><source>Crit. Rev. Biochem. Mol. Biol.</source><year>2013</year><volume>48</volume><fpage>430</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.3109/10409238.2013.819830</pub-id><?supplied-pmid 23879520?><pub-id pub-id-type="pmid">23879520</pub-id></element-citation></ref><ref id="B118-molecules-23-00395"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Structures and target recognition modes of pdz domains: Recurring themes and emerging pictures</article-title><source>Biochem. J.</source><year>2013</year><volume>455</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1042/BJ20130783</pub-id><?supplied-pmid 24028161?><pub-id pub-id-type="pmid">24028161</pub-id></element-citation></ref><ref id="B119-molecules-23-00395"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valiente</surname><given-names>M.</given-names></name><name><surname>Andres-Pons</surname><given-names>A.</given-names></name><name><surname>Gomar</surname><given-names>B.</given-names></name><name><surname>Torres</surname><given-names>J.</given-names></name><name><surname>Gil</surname><given-names>A.</given-names></name><name><surname>Tapparel</surname><given-names>C.</given-names></name><name><surname>Antonarakis</surname><given-names>S.E.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>Binding of pten to specific pdz domains contributes to pten protein stability and phosphorylation by microtubule-associated serine/threonine kinases</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>28936</fpage><lpage>28943</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504761200</pub-id><?supplied-pmid 15951562?><pub-id pub-id-type="pmid">15951562</pub-id></element-citation></ref><ref id="B120-molecules-23-00395"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R.</given-names></name><name><surname>Mason</surname><given-names>W.P.</given-names></name><name><surname>van den Bent</surname><given-names>M.J.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>Fisher</surname><given-names>B.</given-names></name><name><surname>Taphoorn</surname><given-names>M.J.</given-names></name><name><surname>Belanger</surname><given-names>K.</given-names></name><name><surname>Brandes</surname><given-names>A.A.</given-names></name><name><surname>Marosi</surname><given-names>C.</given-names></name><name><surname>Bogdahn</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id><?supplied-pmid 15758009?><pub-id pub-id-type="pmid">15758009</pub-id></element-citation></ref><ref id="B121-molecules-23-00395"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navis</surname><given-names>A.C.</given-names></name><name><surname>van den Eijnden</surname><given-names>M.</given-names></name><name><surname>Schepens</surname><given-names>J.T.</given-names></name><name><surname>Hooft van Huijsduijnen</surname><given-names>R.</given-names></name><name><surname>Wesseling</surname><given-names>P.</given-names></name><name><surname>Hendriks</surname><given-names>W.J.</given-names></name></person-group><article-title>Protein tyrosine phosphatases in glioma biology</article-title><source>Acta Neuropathol.</source><year>2010</year><volume>119</volume><fpage>157</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0614-0</pub-id><?supplied-pmid 19936768?><pub-id pub-id-type="pmid">19936768</pub-id></element-citation></ref><ref id="B122-molecules-23-00395"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgonje</surname><given-names>A.M.</given-names></name><name><surname>Verrijp</surname><given-names>K.</given-names></name><name><surname>Schepens</surname><given-names>J.T.</given-names></name><name><surname>Navis</surname><given-names>A.C.</given-names></name><name><surname>Piepers</surname><given-names>J.A.</given-names></name><name><surname>Palmen</surname><given-names>C.B.</given-names></name><name><surname>van den Eijnden</surname><given-names>M.</given-names></name><name><surname>Hooft van Huijsduijnen</surname><given-names>R.</given-names></name><name><surname>Wesseling</surname><given-names>P.</given-names></name><name><surname>Leenders</surname><given-names>W.P.</given-names></name><etal/></person-group><article-title>Comprehensive protein tyrosine phosphatase mrna profiling identifies new regulators in the progression of glioma</article-title><source>Acta Neuropathol. Commun.</source><year>2016</year><volume>4</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s40478-016-0372-x</pub-id><?supplied-pmid 27586084?><pub-id pub-id-type="pmid">27586084</pub-id></element-citation></ref><ref id="B123-molecules-23-00395"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotelo</surname><given-names>N.S.</given-names></name><name><surname>Schepens</surname><given-names>J.T.G.</given-names></name><name><surname>Valiente</surname><given-names>M.</given-names></name><name><surname>Hendriks</surname><given-names>W.</given-names></name><name><surname>Pulido</surname><given-names>R.</given-names></name></person-group><article-title>Pten-pdz domain interactions: Binding of pten to pdz domains of ptpn13</article-title><source>Methods</source><year>2015</year><volume>77&#8211;78</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2014.10.017</pub-id><?supplied-pmid 25448478?><pub-id pub-id-type="pmid">25448478</pub-id></element-citation></ref><ref id="B124-molecules-23-00395"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnea</surname><given-names>G.</given-names></name><name><surname>Grumet</surname><given-names>M.</given-names></name><name><surname>Milev</surname><given-names>P.</given-names></name><name><surname>Silvennoinen</surname><given-names>O.</given-names></name><name><surname>Levy</surname><given-names>J.B.</given-names></name><name><surname>Sap</surname><given-names>J.</given-names></name><name><surname>Schlessinger</surname><given-names>J.</given-names></name></person-group><article-title>Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>14349</fpage><lpage>14352</lpage><?supplied-pmid 7514167?><pub-id pub-id-type="pmid">7514167</pub-id></element-citation></ref><ref id="B125-molecules-23-00395"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgonje</surname><given-names>A.M.</given-names></name><name><surname>Navis</surname><given-names>A.C.</given-names></name><name><surname>Schepens</surname><given-names>J.T.</given-names></name><name><surname>Verrijp</surname><given-names>K.</given-names></name><name><surname>Hovestad</surname><given-names>L.</given-names></name><name><surname>Hilhorst</surname><given-names>R.</given-names></name><name><surname>Harroch</surname><given-names>S.</given-names></name><name><surname>Wesseling</surname><given-names>P.</given-names></name><name><surname>Leenders</surname><given-names>W.P.</given-names></name><name><surname>Hendriks</surname><given-names>W.J.</given-names></name></person-group><article-title>Intracellular and extracellular domains of protein tyrosine phosphatase ptprz-b differentially regulate glioma cell growth and motility</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>8690</fpage><lpage>8702</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2366</pub-id><?supplied-pmid 25238264?><pub-id pub-id-type="pmid">25238264</pub-id></element-citation></ref><ref id="B126-molecules-23-00395"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foehr</surname><given-names>E.D.</given-names></name><name><surname>Lorente</surname><given-names>G.</given-names></name><name><surname>Kuo</surname><given-names>J.</given-names></name><name><surname>Ram</surname><given-names>R.</given-names></name><name><surname>Nikolich</surname><given-names>K.</given-names></name><name><surname>Urfer</surname><given-names>R.</given-names></name></person-group><article-title>Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>2271</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1221</pub-id><?supplied-pmid 16489031?><pub-id pub-id-type="pmid">16489031</pub-id></element-citation></ref><ref id="B127-molecules-23-00395"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname><given-names>A.</given-names></name><name><surname>Nagahira</surname><given-names>A.</given-names></name><name><surname>Sugawara</surname><given-names>H.</given-names></name><name><surname>Ishii</surname><given-names>K.</given-names></name><name><surname>Imajo</surname><given-names>S.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Kuboyama</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>R.</given-names></name><name><surname>Tanga</surname><given-names>N.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Small-molecule inhibition of ptprz reduces tumor growth in a rat model of glioblastoma</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>20473</fpage><pub-id pub-id-type="doi">10.1038/srep20473</pub-id><?supplied-pmid 26857455?><pub-id pub-id-type="pmid">26857455</pub-id></element-citation></ref><ref id="B128-molecules-23-00395"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampling</surname><given-names>R.</given-names></name><name><surname>Peoples</surname><given-names>S.</given-names></name><name><surname>Mulholland</surname><given-names>P.J.</given-names></name><name><surname>James</surname><given-names>A.</given-names></name><name><surname>Al-Salihi</surname><given-names>O.</given-names></name><name><surname>Twelves</surname><given-names>C.J.</given-names></name><name><surname>McBain</surname><given-names>C.</given-names></name><name><surname>Jefferies</surname><given-names>S.</given-names></name><name><surname>Jackson</surname><given-names>A.</given-names></name><name><surname>Stewart</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A cancer research uk first time in human phase i trial of ima950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma</article-title><source>Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>4776</fpage><lpage>4785</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0506</pub-id><?supplied-pmid 27225692?><pub-id pub-id-type="pmid">27225692</pub-id></element-citation></ref><ref id="B129-molecules-23-00395"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawachi</surname><given-names>H.</given-names></name><name><surname>Tamura</surname><given-names>H.</given-names></name><name><surname>Watakabe</surname><given-names>I.</given-names></name><name><surname>Shintani</surname><given-names>T.</given-names></name><name><surname>Maeda</surname><given-names>N.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>Protein tyrosine phosphatase zeta/rptpbeta interacts with psd-95/sap90 family</article-title><source>Brain Res. Mol. Brain Res.</source><year>1999</year><volume>72</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S0169-328X(99)00204-1</pub-id><pub-id pub-id-type="pmid">10521598</pub-id></element-citation></ref><ref id="B130-molecules-23-00395"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appert-Collin</surname><given-names>A.</given-names></name><name><surname>Hubert</surname><given-names>P.</given-names></name><name><surname>Cremel</surname><given-names>G.</given-names></name><name><surname>Bennasroune</surname><given-names>A.</given-names></name></person-group><article-title>Role of erbb receptors in cancer cell migration and invasion</article-title><source>Front. Pharmacol.</source><year>2015</year><volume>6</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.3389/fphar.2015.00283</pub-id><?supplied-pmid 26635612?><pub-id pub-id-type="pmid">26635612</pub-id></element-citation></ref><ref id="B131-molecules-23-00395"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname><given-names>A.</given-names></name><name><surname>Chow</surname><given-names>J.P.</given-names></name><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Fukada</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>R.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>Tyrosine phosphorylation of erbb4 is enhanced by psd95 and repressed by protein tyrosine phosphatase receptor type z</article-title><source>J. Biochem.</source><year>2007</year><volume>142</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1093/jb/mvm140</pub-id><?supplied-pmid 17646177?><pub-id pub-id-type="pmid">17646177</pub-id></element-citation></ref><ref id="B132-molecules-23-00395"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwakura</surname><given-names>Y.</given-names></name><name><surname>Nawa</surname><given-names>H.</given-names></name></person-group><article-title>Erbb1-4-dependent egf/neuregulin signals and their cross talk in the central nervous system: Pathological implications in schizophrenia and parkinson's disease</article-title><source>Front. Cell. Neurosci.</source><year>2013</year><volume>7</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.3389/fncel.2013.00004</pub-id><?supplied-pmid 23408472?><pub-id pub-id-type="pmid">23408472</pub-id></element-citation></ref><ref id="B133-molecules-23-00395"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>A.</given-names></name><name><surname>Clausen</surname><given-names>B.H.</given-names></name><name><surname>Moller</surname><given-names>M.</given-names></name><name><surname>Vestergaard</surname><given-names>B.</given-names></name><name><surname>Chi</surname><given-names>C.N.</given-names></name><name><surname>Round</surname><given-names>A.</given-names></name><name><surname>Sorensen</surname><given-names>P.L.</given-names></name><name><surname>Nissen</surname><given-names>K.B.</given-names></name><name><surname>Kastrup</surname><given-names>J.S.</given-names></name><name><surname>Gajhede</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A high-affinity, dimeric inhibitor of psd-95 bivalently interacts with pdz1&#8211;2 and protects against ischemic brain damage</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>3317</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1073/pnas.1113761109</pub-id><?supplied-pmid 22343531?><pub-id pub-id-type="pmid">22343531</pub-id></element-citation></ref><ref id="B134-molecules-23-00395"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxbaum</surname><given-names>J.D.</given-names></name><name><surname>Georgieva</surname><given-names>L.</given-names></name><name><surname>Young</surname><given-names>J.J.</given-names></name><name><surname>Plescia</surname><given-names>C.</given-names></name><name><surname>Kajiwara</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Moskvina</surname><given-names>V.</given-names></name><name><surname>Norton</surname><given-names>N.</given-names></name><name><surname>Peirce</surname><given-names>T.</given-names></name><name><surname>Williams</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Molecular dissection of nrg1-erbb4 signaling implicates ptprz1 as a potential schizophrenia susceptibility gene</article-title><source>Mol. Psychiatry</source><year>2008</year><volume>13</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001991</pub-id><?supplied-pmid 17579610?><pub-id pub-id-type="pmid">17579610</pub-id></element-citation></ref><ref id="B135-molecules-23-00395"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname><given-names>A.</given-names></name><name><surname>Fukada</surname><given-names>M.</given-names></name><name><surname>Makioka</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>R.</given-names></name><name><surname>Chow</surname><given-names>J.P.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>Consensus substrate sequence for protein-tyrosine phosphatase receptor type z</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>37137</fpage><lpage>37146</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.270140</pub-id><?supplied-pmid 21890632?><pub-id pub-id-type="pmid">21890632</pub-id></element-citation></ref><ref id="B136-molecules-23-00395"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamsky</surname><given-names>K.</given-names></name><name><surname>Arnold</surname><given-names>K.</given-names></name><name><surname>Sabanay</surname><given-names>H.</given-names></name><name><surname>Peles</surname><given-names>E.</given-names></name></person-group><article-title>Junctional protein magi-3 interacts with receptor tyrosine phosphatase beta (rptp beta) and tyrosine-phosphorylated proteins</article-title><source>J. Cell Sci.</source><year>2003</year><volume>116</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1242/jcs.00302</pub-id><?supplied-pmid 12615970?><pub-id pub-id-type="pmid">12615970</pub-id></element-citation></ref><ref id="B137-molecules-23-00395"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrosotskaya</surname><given-names>I.Y.</given-names></name><name><surname>James</surname><given-names>G.L.</given-names></name></person-group><article-title>Magi-1 interacts with beta-catenin and is associated with cell-cell adhesion structures</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2000</year><volume>270</volume><fpage>903</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2471</pub-id><?supplied-pmid 10772923?><pub-id pub-id-type="pmid">10772923</pub-id></element-citation></ref><ref id="B138-molecules-23-00395"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>B.T.</given-names></name><name><surname>Tamai</surname><given-names>K.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name></person-group><article-title>Wnt/beta-catenin signaling: Components, mechanisms, and diseases</article-title><source>Dev. Cell</source><year>2009</year><volume>17</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id><?supplied-pmid 19619488?><pub-id pub-id-type="pmid">19619488</pub-id></element-citation></ref><ref id="B139-molecules-23-00395"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukada</surname><given-names>M.</given-names></name><name><surname>Kawachi</surname><given-names>H.</given-names></name><name><surname>Fujikawa</surname><given-names>A.</given-names></name><name><surname>Noda</surname><given-names>M.</given-names></name></person-group><article-title>Yeast substrate-trapping system for isolating substrates of protein tyrosine phosphatases: Isolation of substrates for protein tyrosine phosphatase receptor type z</article-title><source>Methods</source><year>2005</year><volume>35</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2004.07.008</pub-id><?supplied-pmid 15588986?><pub-id pub-id-type="pmid">15588986</pub-id></element-citation></ref><ref id="B140-molecules-23-00395"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freiss</surname><given-names>G.</given-names></name><name><surname>Chalbos</surname><given-names>D.</given-names></name></person-group><article-title>Ptpn13/ptpl1: An important regulator of tumor aggressiveness</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2011</year><volume>11</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.2174/187152011794941262</pub-id></element-citation></ref><ref id="B141-molecules-23-00395"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Irie</surname><given-names>S.</given-names></name><name><surname>Kitada</surname><given-names>S.</given-names></name><name><surname>Reed</surname><given-names>J.C.</given-names></name></person-group><article-title>Fap-1: A protein tyrosine phosphatase that associates with fas</article-title><source>Science</source><year>1995</year><volume>268</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1126/science.7536343</pub-id><?supplied-pmid 7536343?><pub-id pub-id-type="pmid">7536343</pub-id></element-citation></ref><ref id="B142-molecules-23-00395"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gump</surname><given-names>J.M.</given-names></name><name><surname>Staskiewicz</surname><given-names>L.</given-names></name><name><surname>Morgan</surname><given-names>M.J.</given-names></name><name><surname>Bamberg</surname><given-names>A.</given-names></name><name><surname>Riches</surname><given-names>D.W.</given-names></name><name><surname>Thorburn</surname><given-names>A.</given-names></name></person-group><article-title>Autophagy variation within a cell population determines cell fate through selective degradation of fap-1</article-title><source>Nat. Cell Biol.</source><year>2014</year><volume>16</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/ncb2886</pub-id><?supplied-pmid 24316673?><pub-id pub-id-type="pmid">24316673</pub-id></element-citation></ref><ref id="B143-molecules-23-00395"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Luan</surname><given-names>C.H.</given-names></name><name><surname>Hjort</surname><given-names>E.E.</given-names></name><name><surname>Bei</surname><given-names>L.</given-names></name><name><surname>Mishra</surname><given-names>R.</given-names></name><name><surname>Sakamoto</surname><given-names>K.M.</given-names></name><name><surname>Platanias</surname><given-names>L.C.</given-names></name><name><surname>Eklund</surname><given-names>E.A.</given-names></name></person-group><article-title>The role of fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia</article-title><source>Leukemia</source><year>2016</year><volume>30</volume><fpage>1502</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1038/leu.2016.66</pub-id><?supplied-pmid 26984787?><pub-id pub-id-type="pmid">26984787</pub-id></element-citation></ref><ref id="B144-molecules-23-00395"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revillion</surname><given-names>F.</given-names></name><name><surname>Puech</surname><given-names>C.</given-names></name><name><surname>Rabenoelina</surname><given-names>F.</given-names></name><name><surname>Chalbos</surname><given-names>D.</given-names></name><name><surname>Peyrat</surname><given-names>J.P.</given-names></name><name><surname>Freiss</surname><given-names>G.</given-names></name></person-group><article-title>Expression of the putative tumor suppressor gene ptpn13/ptpl1 is an independent prognostic marker for overall survival in breast cancer</article-title><source>Int. J. Cancer</source><year>2009</year><volume>124</volume><fpage>638</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1002/ijc.23989</pub-id><?supplied-pmid 19004008?><pub-id pub-id-type="pmid">19004008</pub-id></element-citation></ref><ref id="B145-molecules-23-00395"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>Parsons</surname><given-names>D.W.</given-names></name><name><surname>Bardelli</surname><given-names>A.</given-names></name><name><surname>Sager</surname><given-names>J.</given-names></name><name><surname>Szabo</surname><given-names>S.</given-names></name><name><surname>Ptak</surname><given-names>J.</given-names></name><name><surname>Silliman</surname><given-names>N.</given-names></name><name><surname>Peters</surname><given-names>B.A.</given-names></name><name><surname>van der Heijden</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Mutational analysis of the tyrosine phosphatome in colorectal cancers</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1164</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1126/science.1096096</pub-id><?supplied-pmid 15155950?><pub-id pub-id-type="pmid">15155950</pub-id></element-citation></ref><ref id="B146-molecules-23-00395"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>A.C.</given-names></name><name><surname>Strand</surname><given-names>G.L.</given-names></name><name><surname>Nowicki</surname><given-names>P.N.</given-names></name><name><surname>Anderson</surname><given-names>M.E.</given-names></name><name><surname>Vermeer</surname><given-names>P.D.</given-names></name><name><surname>Klingelhutz</surname><given-names>A.J.</given-names></name><name><surname>Bossler</surname><given-names>A.D.</given-names></name><name><surname>Pottala</surname><given-names>J.V.</given-names></name><name><surname>Hendriks</surname><given-names>W.J.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>Impaired ptpn13 phosphatase activity in spontaneous or hpv-induced squamous cell carcinomas potentiates oncogene signaling through the map kinase pathway</article-title><source>Oncogene</source><year>2009</year><volume>28</volume><fpage>3960</fpage><lpage>3970</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.251</pub-id><?supplied-pmid 19734941?><pub-id pub-id-type="pmid">19734941</pub-id></element-citation></ref><ref id="B147-molecules-23-00395"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abaan</surname><given-names>O.D.</given-names></name><name><surname>Levenson</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>O.</given-names></name><name><surname>Furth</surname><given-names>P.A.</given-names></name><name><surname>Uren</surname><given-names>A.</given-names></name><name><surname>Toretsky</surname><given-names>J.A.</given-names></name></person-group><article-title>Ptpl1 is a direct transcriptional target of ews-fli1 and modulates ewing's sarcoma tumorigenesis</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>2715</fpage><lpage>2722</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208247</pub-id><?supplied-pmid 15782144?><pub-id pub-id-type="pmid">15782144</pub-id></element-citation></ref><ref id="B148-molecules-23-00395"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>L.</given-names></name><name><surname>Dittmar</surname><given-names>T.</given-names></name><name><surname>Erdmann</surname><given-names>K.S.</given-names></name></person-group><article-title>The protein tyrosine phosphatase ptp-bl associates with the midbody and is involved in the regulation of cytokinesis</article-title><source>Mol. Biol. Cell</source><year>2003</year><volume>14</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1091/mbc.E02-04-0191</pub-id><?supplied-pmid 12529439?><pub-id pub-id-type="pmid">12529439</pub-id></element-citation></ref><ref id="B149-molecules-23-00395"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>D.N.</given-names></name><name><surname>Perry</surname><given-names>A.</given-names></name><name><surname>Reifenberger</surname><given-names>G.</given-names></name><name><surname>von Deimling</surname><given-names>A.</given-names></name><name><surname>Figarella-Branger</surname><given-names>D.</given-names></name><name><surname>Cavenee</surname><given-names>W.K.</given-names></name><name><surname>Ohgaki</surname><given-names>H.</given-names></name><name><surname>Wiestler</surname><given-names>O.D.</given-names></name><name><surname>Kleihues</surname><given-names>P.</given-names></name><name><surname>Ellison</surname><given-names>D.W.</given-names></name></person-group><article-title>The 2016 world health organization classification of tumors of the central nervous system: A summary</article-title><source>Acta Neuropathol.</source><year>2016</year><volume>131</volume><fpage>803</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1545-1</pub-id><?supplied-pmid 27157931?><pub-id pub-id-type="pmid">27157931</pub-id></element-citation></ref><ref id="B150-molecules-23-00395"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palma</surname><given-names>L.</given-names></name><name><surname>Celli</surname><given-names>P.</given-names></name><name><surname>Maleci</surname><given-names>A.</given-names></name><name><surname>Di Lorenzo</surname><given-names>N.</given-names></name><name><surname>Cantore</surname><given-names>G.</given-names></name></person-group><article-title>Malignant monstrocellular brain tumours. A study of 42 surgically treated cases</article-title><source>Acta neurochir.</source><year>1989</year><volume>97</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/BF01577735</pub-id><?supplied-pmid 2718792?><pub-id pub-id-type="pmid">2718792</pub-id></element-citation></ref><ref id="B151-molecules-23-00395"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivas</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>J.P.</given-names></name><name><surname>Yang</surname><given-names>C.C.</given-names></name><name><surname>Sun</surname><given-names>S.M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>A.M.</given-names></name><name><surname>Jensen</surname><given-names>J.</given-names></name><name><surname>Licon</surname><given-names>K.</given-names></name><name><surname>Bojorquez-Gomez</surname><given-names>A.</given-names></name><name><surname>Klepper</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A network of conserved synthetic lethal interactions for exploration of precision cancer therapy</article-title><source>Mol. Cell</source><year>2016</year><volume>63</volume><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.022</pub-id><?supplied-pmid 27453043?><pub-id pub-id-type="pmid">27453043</pub-id></element-citation></ref><ref id="B152-molecules-23-00395"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>S.</given-names></name><name><surname>Kitagishi</surname><given-names>Y.</given-names></name></person-group><article-title>Magi scaffolding molecules involved in cancer cell signaling</article-title><source>J. Carcinog. Mutagen.</source><year>2013</year><volume>S7</volume><fpage>005</fpage></element-citation></ref><ref id="B153-molecules-23-00395"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Ping</surname><given-names>Y.F.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>Z.C.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Bian</surname><given-names>B.S.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.C.</given-names></name><etal/></person-group><article-title>Tumour-associated macrophages secrete pleiotrophin to promote ptprz1 signalling in glioblastoma stem cells for tumour growth</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15080</fpage><pub-id pub-id-type="doi">10.1038/ncomms15080</pub-id><?supplied-pmid 28569747?><pub-id pub-id-type="pmid">28569747</pub-id></element-citation></ref><ref id="B154-molecules-23-00395"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kegelman</surname><given-names>T.P.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Das</surname><given-names>S.K.</given-names></name><name><surname>Talukdar</surname><given-names>S.</given-names></name><name><surname>Beckta</surname><given-names>J.M.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Valerie</surname><given-names>K.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Furnari</surname><given-names>F.B.</given-names></name><etal/></person-group><article-title>Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of mda-9/syntenin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1073/pnas.1616100114</pub-id><?supplied-pmid 28011764?><pub-id pub-id-type="pmid">28011764</pub-id></element-citation></ref><ref id="B155-molecules-23-00395"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanos</surname><given-names>W.C.</given-names></name><name><surname>Hoover</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>G.F.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Strand</surname><given-names>G.L.</given-names></name><name><surname>Anderson</surname><given-names>M.E.</given-names></name><name><surname>Klingelhutz</surname><given-names>A.J.</given-names></name><name><surname>Hendriks</surname><given-names>W.</given-names></name><name><surname>Bossler</surname><given-names>A.D.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>The pdz binding motif of human papillomavirus type 16 e6 induces ptpn13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>2493</fpage><lpage>2500</lpage><pub-id pub-id-type="doi">10.1128/JVI.02188-07</pub-id><?supplied-pmid 18160445?><pub-id pub-id-type="pmid">18160445</pub-id></element-citation></ref><ref id="B156-molecules-23-00395"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trave</surname><given-names>G.</given-names></name></person-group><article-title>Pdz-peptide complexes: As exciting as ever</article-title><source>Structure</source><year>2011</year><volume>19</volume><fpage>1350</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.09.008</pub-id><?supplied-pmid 22000506?><pub-id pub-id-type="pmid">22000506</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-23-00395-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Classification and protein domain structure of PTPs discussed in this manuscript. Top five bars summarize the family&#8217;s (sub)class build-up, with number of genes indicated in between brackets. In the lower part, gene (italics) and protein names of representative PTPs, as well as the structures of fourteen PTP types are given. Horizontal twin black lines represent the plasma membrane. Protein domain representations are explained on the right. CAD, carbonic anhydrase-like; C2, protein kinase C conserved region; D2, inactive PTP domain; FERM, 4.1 protein-ezrin-radixin-moesin; FNIII, Fibronectin type three; Ig-like, Immunoglobulin-like; KIND, kinase non-catalytic C-lobe; MAM, meprin, A-5 protein, and RPTP-mu; PDZ, postsynaptic density-95/discs large/ZO1 homology; PTP, catalytic domain; SH2, Src Homology 2. Based on [<xref rid="B2-molecules-23-00395" ref-type="bibr">2</xref>,<xref rid="B6-molecules-23-00395" ref-type="bibr">6</xref>].</p></caption><graphic xlink:href="molecules-23-00395-g001"/></fig><fig id="molecules-23-00395-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Protein interaction-dependent regulatory mechanisms impinging on PTPs. (<bold>A</bold>) Intramolecular interactions between membrane-proximal and -distal PTP domains may boost or attenuate enzymatic activity. (<bold>B</bold>) Dimerization of RPTPs usually inhibits enzyme activity. (<bold>C</bold>) Active PTEN homodimers form once the C-terminal part is dephosphorylated. (<bold>D</bold>) PRLs trimer formation enables enzyme activity. (<bold>E</bold>) SH2-containing PTPs are activated by phosphotyrosine-containing ligands. (<bold>F</bold>) Interactions between the CDC25-like domain in MAP kinase phosphatases and the substrate MAPK boost PTP activity. (<bold>G</bold>) PDZ target sequences, upon binding to PDZ domains in PTPs, trigger enzymatic activity of the latter. (<bold>H</bold>) Heterodimerization with inactive members of the MTMR subfamily boosts the enzymatic function of active subfamily members. (<bold>I</bold>) Submembranous PDZ domains trigger enzymatic activity upon binding to PDZ target sequences in RPTPs. (<bold>J</bold>) Submembranous complexes with PDZ-containing proteins are able to recruit the activity of PDZ target sequence-containing PTPs. For more details on these types of regulation and the associated references we refer to the text.</p></caption><graphic xlink:href="molecules-23-00395-g002"/></fig><fig id="molecules-23-00395-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Approaches to interfere with protein&#8211;protein interactions: (<bold>A</bold>) small compounds (upper) or RNAi-based drugs (lower); (<bold>B</bold>) linear interfering peptides; (<bold>C</bold>) stabilized, (bi)cyclic peptides; (<bold>D</bold>) scaffolds; (<bold>E</bold>) protein fragments; and (<bold>F</bold>) protein domains. Images are based on PDB-derived structures of DNA-binding compound DB1804 (A: 3U05), cell penetrating peptide Penetretin (B: 2ND6), one half of a sunflower trypsin inhibitor-1-derived, backbone-cyclized disulfide-bridged 16-mer peptide (C: 2BEY), a tubulin-binding Darpin (D: 5NQU; binding interface is formed by the lower-right loops), the single chain antibody fragment scA21 against ErbB2 (E: 2GJJ; antigen binding site is on the left), and the second PDZ domain in PTPN13 (F: 1GM1; the ligand, a C-terminal PDZ target site, will bind in the groove formed by the top alpha helical structure and the beta strand that runs parallel).</p></caption><graphic xlink:href="molecules-23-00395-g003"/></fig><fig id="molecules-23-00395-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Current examples of proteinaceous PTP modulators. (<bold>A</bold>) Regulation of RPTP&#963; activity by CSPG or HSPG ligands, dimerizing antibodies (4.5H5), dimerization-blocking decoy receptors or a cell-penetrating &#8220;wedge&#8221; peptide (ISP). In addition, cyclic peptide dimers that activate CD148 are shown. (<bold>B</bold>) Inhibition of PTP1B activity by a bicyclic peptide containing a cell-penetrating and an enzyme-inhibiting peptide loop, or by an intracellular single-chain variable fragment (scFv45) that stabilizes the partly oxidized, inactive form of the enzyme. (<bold>C</bold>) Abrogation of the ligand-induced activation of SHP2 using a monobody that blocks SH2 domain interactions with the ligand. (<bold>D</bold>) Interfering with PDZ-mediated regulatory principles. Cell-penetrating peptides (CPP) prevent PTEN recruitment to the postsynaptic density (upper half) or activate PTPN4 in glioblastoma cells (lower part). (<bold>E</bold>) Schematic depiction of targetable submembranous PDZ-based interactions in glioblastoma cells. PTEN, PTPRZ-B, ErbB4 and &#946;-catenin all can interact with PSD95, MAGI family members and PTPN13 PDZ domains. Associations may be mutually exclusive, as for PTEN and PTPRZ-B binding to PTPN13 PDZ2, or additive. The ErbB4 TK domain is in green, blue diamonds represent &#946;-catenin armadillo repeats, and the green rectangle indicates the membrane-associated guanylate kinase domain in PSD95 and MAGI proteins. Other protein domains are explained in <xref ref-type="fig" rid="molecules-23-00395-f001">Figure 1</xref>. See the text for more details and references.</p></caption><graphic xlink:href="molecules-23-00395-g004"/></fig></floats-group></article>